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Abstract 
 
Type 2 diabetes (T2D) is a leading cause of global morbidity and mortality 
characterised by deficits in insulin secretion and function. Diabetes’ poor health 
outcomes are largely attributed to its macrovascular and microvascular 
complications, which can be prevented by ensuring adequate glycaemic control. 
Current guidance recommends optimising lifestyle interventions (weight loss and 
exercise) as first line management in T2D progressing to oral pharmacotherapy 
with metformin. If however poor glycaemic control persists, second and third line 
agents are added. The numerous glucose-lowering agents available and a lack 
of robust comparative outcome data make selecting the most appropriate second 
and third line therapies for individuals with T2D a major clinical dilemma. 
There is huge inter-individual variation in response to type 2 diabetes medication: 
some individuals may elicit a significant glucose-lowering response to one 
medication, but the same medication may have little effect on others. As diabetes 
is a heterogeneous disease (a disease likely manifesting from multiple 
aetiologies) it is likely that a biological basis partly underpins the variation in 
therapeutic response. These disease attributes suggest the potential for the 
integration of a stratified approach to diabetes therapy. Stratification involves 
prescribing medication based on factors other than patients’ presenting 
symptoms; such as phenotypic traits or biomarkers. The main aim of stratification 
is to identify and provide individualised therapies that maximise therapeutic 
efficacy and minimise adverse events. 
Limited research has been conducted into the mechanisms underpinning 
variation in diabetes treatment response. The main aim of this thesis is to 
investigate potential mechanisms underpinning the inter-individual variation in 
response to sitagliptin (a DPP-4 inhibitor) and gliclazide (a sulphonylurea) using 
data from the MASTERMIND randomised control crossover trial. This will aid in 
understanding variation in therapeutic response in T2D and support the 
development of a stratified approach.  
Chapter 1 provides an overview of stratified medicine and introduces T2D as a 
potential candidate for stratification. In this chapter, we also review the literature 
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surrounding the pharmacokinetics of sitagliptin and gliclazide, the agents 
investigated in this thesis to answer questions of stratification and inter-individual 
variation in therapeutic response.  
Chapter 2 provides a detailed overview of the MASTERMIND randomised control 
crossover study design, from which data for this thesis was analysed. 
Chapter 3 explores potential associations between trough and total plasma drug 
levels and (fasting and post-prandial plasma) glucose response to sitagliptin and 
gliclazide. We found that while plasma drug levels were highly variable this 
variation did not substantially explain short term glycaemic response to these 
agents. 
In Chapter 4 we assess whether medication adherence, calculated using 
medication possession ratio (MPR) is associated with therapeutic response to 
sitagliptin and gliclazide therapy. We found that, in a trial setting most participants 
were adherent to study medication and that variation in adherence did not explain 
variation in glucose-lowering response in this setting.  
In Chapter 5 we explore whether measurable differences in lifestyle factors 
explain the variation in glucose-lowering response to sitagliptin and gliclazide by 
analysing weight and accelerometer data. We show that both weight and physical 
activity were stable within an individual during the study period and that individual 
differences of these lifestyle factors between each treatment period, do not 
explain the corresponding differences in glycaemic responses. 
Chapter 6 investigates whether glucose-lowering response to diabetes therapy is 
specific to an individual. We show that the change in fasting glycaemia from after 
stopping sulphonylurea (SU) therapy strongly correlates with the fasting 
glycaemic response observed when re-starting SU therapy but does not predict 
fasting glycaemic response to DPP-4 inhibitor therapy.  
An overview of the major finding of each chapter and their implications for future 
precision medicine research in diabetes is discussed in Chapter 7. 
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1. Introduction 
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1.1 Applying a Stratified Approach to Type 2 
Diabetes 
 
1.1.1 The Burden of Type 2 Diabetes Mellitus  
With an estimated global prevalence of 422 million [1],  Type 2 Diabetes Mellitus 
(T2D) is a significant burden to modern society. This figure is expected to rise to 
642 million by 2040 [1], and can largely be attributed to sedentary lifestyle, an 
ageing population and an increased incidence in obesity [2].  
T2D is a disease characterised by deficits in insulin secretion and function, 
leading to raised blood glucose levels (hyperglycaemia) [3].  Observational 
studies have  reported a relationship between the extent of hyperglycaemia and 
an increased risk of mortality and of macrovascular (cerebrovascular and 
cardiovascular) and microvascular (neuropathy, nephropathy and retinopathy) 
disease within T2D [4–6]. Unfortunately these complications cause significant 
health burdens, including; coronary heart disease, lower extremity amputations, 
end stage renal failure, and blindness [7].  
The effectiveness of tight glycaemic control in preventing diabetes’ microvascular 
complications was established by the Diabetes Control and Complications Trial 
(DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study 
for type 1 diabetes (T1D)[8, 9]. The United Kingdom Prospective Diabetes Study 
(UKPDS) reported how optimising glycaemic control also protected from 
microvascular complications in T2D and demonstrated a reduction in 
macrovascular disease in long term follow up [10].   
The annual cost of treating diabetes and its complications to the National Health 
Service (NHS) in 2016 was reportedly £14 billion[11], with the  International 
Diabetes Federation (IDF) reporting 12% of the global health expenditure spent 
on managing the condition [12].  Despite these huge expenses, robust evidence 
linking sustained hyperglycaemia to poor health outcomes and the numerous 
glucose-lowering agents on the market, glycaemic control remains sub-optimal in 
many patients with T2D [13]. The following section will review current treatment 
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pathways and the challenges faced in pursuit of effective glycaemic 
management. 
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1.1.2 Current Treatment Pathways in Type 2 Diabetes   
Current guidance from the National Institute for Health and Care Excellence 
(NICE) [14], recommends optimising lifestyle interventions as first line in the 
management of T2D. If blood glucose levels remain poorly controlled, oral 
pharmacotherapy is commenced, typically with metformin with new agents added 
(and rarely withdrawn) in a stepwise fashion. There are several hypoglycaemic 
medications available, with the most common current second-line agents 
prescribed in the UK being DPP-4 inhibitor and/or sulphonylurea therapy[15]. If 
patients fail to achieve adequate glycaemic control on oral therapy, eventually 
insulin injections are required [16].  
The lack of robust comparative effectiveness data make selecting second and 
third-line treatment intensifications a huge clinical dilemma, as evidenced by 
recent guidelines[17, 18].  Due to this, choice of second-line glucose-lowering 
agents is largely dictated by cost, physician bias and side effect profile, (rather 
than choosing the most effective drug for that individual).  
1.1.3 Response to glucose-lowering therapy is highly 
variable  
In T2D there is huge variation seen in response to glucose-lowering therapy [18–
21]; some individuals elicit a marked glucose-lowering response to one drug, 
whilst other individuals exhibit no response to the same drug.  The reasons 
underpinning the variation in therapeutic response remain unclear.  
There are several possibilities for heterogeneity in response to glucose lowering 
therapy including; pharmacokinetic differences (i.e. differences in drug 
absorption, transport or metabolism) and pharmacodynamics differences 
(variation in responses occurring when the drug is at the site of action). As 
diabetes drugs target pathways that are defective, it is possible that that the wide 
variation in therapeutic response may reflect the aetiologies underpinning the 
disease[19].  
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1.1.4 Heterogeneity in the Pathogenesis of Type 2 
Diabetes Mellitus  
Diabetes is a heterogeneous disease, best described by Stephen Fajans in his 
1978 Banting Lecture as a syndrome “comprised of a variety of diseases all 
characterised by hyperglycaemia and tissue changes that result from 
heterogeneous aetiological and pathogenetic factors” [20]. These factors include 
an ageing population and associated transitions in lifestyle and culture (such as 
reduced physical activity and an increased incidence in obesity). 
The variation in insulin resistance and deficiency within the T2D cohort may 
reflect the existence of phenotypically heterogeneous subgroups with specific 
pathophysiological characteristics [21]. Furthermore, there is evidence to suggest 
that the variation in T2D pathogenesis and its precursor states may be influenced 
by biological factors such as age, gender and ethnicity [22]. It is possible that 
subgroups of patients with similar biological characteristics and phenotypes, have 
similar therapeutic responses to medications. By investigating glucose 
homeostasis and therapeutic response amongst and between these subgroups, 
it may be possible to identify predictors of therapeutic response, allowing for a 
stratified approach to the medical management of diabetes.  
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1.1.5 Applying a Stratified Approach to Type 2 
Diabetes 
1.1.5.1 Defining ‘Stratified Medicine’ 
The heterogeneity in T2D and in the therapeutic response to glucose-lowering 
agents suggests that diabetes may be an ideal condition for a stratification.  
Stratified medicine is defined as “the differential prescribing of medications or 
treatment regimens to groups of individuals based on attributes other than their 
presenting symptoms resulting from their disease” [23]. In essence, stratification 
is a form of medicine that categorises a population into the most appropriate 
biological groups to determine the optimal therapeutic response [24].  
Stratified medicine is a term often used interchangeably with ‘precision’ or 
‘personalised’ medicine; however some authors argue subtle differences [25] 
[26]. Precision medicine promotes the finer sub-classification of disease, by 
including repeated monitoring of biomarkers to enable the re-tailoring of 
treatment according to an individual’s response [25]. Personalised medicine 
however, incorporates a precise biological stratified approach to treatment in 
addition to appreciating holistic needs of the patient (by encouraging patient 
participation and preference) [26].By identifying therapies that are most effective 
for an individual or a subgroup of patients, stratified medicine serves to maximise 
therapeutic efficacy and minimise adverse medication effects, thus improving 
clinical care.  
NHS England has promoted a ‘personalised medicine’ approach in their NHS 
England 2016 strategy, recognising the importance of both biological and social 
influences in healthcare [25]. This government initiative, highlights how the 
development and implementation of stratification represents a new era in 
medicine; replacing the ‘one size fits all’ and ‘trial and error’ approach that 
permeates current practice [25].  
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1.1.5.2 Success Stories in Stratified Medicine   
The recognition of breast cancer as a heterogeneous disease and subsequent 
implementation of a stratified approach has revolutionised its treatment and has 
significantly reduced mortality rates [27]. In 2012, Curtis and colleagues reported 
over 10 subgroups of breast malignancy and confirmed the disease is 
heterogeneous at a genetic level; with each subgroup responsive to a different 
treatment [28]. Categorising individuals into subgroups necessitates the 
histological grading of the tumour, assessment of hormonal receptor expression 
and the amplification status of the HER2 gene. The use of HER2 as a biomarker 
has become a paramount diagnostic tool and intrinsic to dictating treatment. If the 
HER2 gene is amplified, as in 15% of breast malignancies [29], individuals are 
treated with the monoclonal antibody trastuzumab. This treatment regime has 
dramatically improved patient outcomes; increasing 10-year disease-free survival 
rates from 62.2% to 73.7% [27].Conversely, if histological analysis confirms the 
expression of oestrogen receptors, the oestrogen receptor antagonist tamoxifen 
is prescribed (or in post-menopausal women, the aromatase inhibitor 
anastrazole) due it its increased therapeutic efficacy [30].    
Diabetes has also seen the benefits of stratification following the identification of 
monogenic subgroups facilitating tailored treatment regimens. Maturity Onset 
Diabetes of the Young (MODY) is form of monogenic diabetes; diabetes that is 
caused by a single gene mutation, with the most common being mutations in the 
transcription factor gene HNF1A [31].  MODY comprises a group of autosomal 
dominant disorders and accounts for 1-2% of all cases of diabetes, with patients 
being diagnosed typically before the age of 25 [24]. Due to its non-ketotic and/or 
non-acute presentation, MODY was once confused with cases T2D in children 
and adolescents[32]. Despite this, patients were and are still frequently 
misdiagnosed with having T1D due to their young presentation. 
To date, pathogenic variants of 14 genes have been identified to cause MODY, 
with the most common being: GCK-MODY, and hepatic nuclear factor (HNF) 1A-
, 4A- and 1B- MODY. Each specific MODY genetic subtype has a unique clinical 
picture and determines a specific treatment regimen [24].  Patients with GCK-
MODY have stable, raised plasma glucose levels, however patients with 
transcription factor-linked MODY show a progressive deterioration of plasma 
glucose levels over time [24]. Patients with the HNF4A mutation present with 
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foetal macrosomia and neonatal hypoglycaemia, whilst glycosuria is a more 
typical symptom of individuals with HNF1A-MODY. In patients with HNF1B 
MODY however, organ- related developmental disorders predominate [33]. 
The most significant clinical feature associated with precision medicine in 
patients with MODY is the differential treatment response in its genetic 
subgroups [24]. As previously mentioned, MODY patients were often 
misdiagnosed with T1D and therefore treated with insulin.  However, patients 
with GCK-MODY were observed to  have similar average blood glucose levels 
irrespective of whether they receive insulin, sulphonylurea therapy, or no glucose 
lowering therapy at all [34]. This finding has meant that , most patients with GCK-
MODY do not require glucose-lowering therapy [33–36]. Similarly individuals with 
HNF1A- and HNF4A- MODY exhibit high sensitivity to sulphonylureas [33, 35–
38]. Stratified medicine has revolutionised therapy for these patients with MODY; 
as following the confirmation of their genetic diagnosis, insulin injections can be 
safely discontinued.  
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1.1.5.3 Is T2D is an appropriate condition for stratification?  
The heterogeneity in the pathogenesis and treatment response in T2D suggests 
that the condition may benefit from stratification. It is possible that subgroups of 
patients with similar biological characteristics and phenotypes, have similar 
responses to glucose-lowering agents. By investigating glucose homeostasis and 
therapeutic response amongst and between these subgroups, it may be possible 
to identify predictors of therapeutic response and identify patients that are most 
likely to respond to therapy and/or least likely to suffer adverse effects [39]. This 
will prevent the unnecessary expense of ineffective treatments whilst also 
ensuring maximal therapeutic benefit and minimising harm.  Unfortunately, very 
little is known about the best approach to studying variation of treatment response 
in diabetes or in other chronic diseases and key questions remain unanswered.  
Is variation in response a reproducible biological characteristic of an 
individual which can therefore potentially be predicted? 
Blood glucose levels fluctuate daily, however the extent to which glycaemic 
response to medication is influenced by reproducible and predictable intrinsic 
factors as opposed to extrinsic factors (such as diet, physical activity and 
medication adherence) is unknown.  
Variations in extrinsic factors contribute to ‘noise’ when assessing variations in 
glycaemia in clinical practice and in research cohorts. Understanding the 
contribution of these factors may aid design of studies in this area, as measuring 
(and adjusting for) these factors will provide a more robust and accurate 
assessment glycaemic variation. If variation in apparent glucose lowering 
response is entirely due to ‘noise’ and not a biological characteristic of an 
individual, then a stratified approach to T2D will not be feasible.  
Is variation in response to glucose-lowering therapy specific?  
Although some individuals appear to be non-responders to hypoglycaemic 
agents, the extent to which the lack of response in clinical practice reflects non-
adherence rather than an intrinsic lack of response is yet to be determined. 
Furthermore, it may be that intrinsic poor response to therapy is an attribute of an 
individual and does not vary by agent, in other words a patient may have disease 
features that mean they respond poorly to all medication. A stratified approach to 
diabetes therapy will only be possible if robust clinical trials demonstrate that poor 
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response to one medicine may be associated with good response to another 
glucose-lowering agent with a different mechanism of action; rather than a lack 
of response to all categories of glucose lowering medication.  
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1.2 The potential role of variation in drug levels 
for explaining variation in response. 
1.2.1 Drug levels as a potential explanation for 
variation in therapeutic response 
 
 A potential candidate that may influence variation in treatment response is 
variation in achieved plasma drug levels. For most hypoglycaemic agents in T2D, 
it is standard practice to prescribe a standard/single dose of a drug, irrespective 
of an individual’s characteristic (such as body weight, height etc). It is therefore 
likely that different individuals have different exposure to a drug; a potential cause 
of variation therapeutic response. Plasma drug concentrations have been shown 
to be associated with therapeutic response to treatment in several other diseases 
[40–42]; however whether variations in plasma drug levels are associated with 
variation in glycaemic response in T2D is not known. 
Outside of diabetes studies, research in a number of conditions have shown 
relationships between drug levels and response, although these studies are often 
limited by small sample size [40–42]. Studies performed in patients with 
rheumatoid arthritis (RA) have shown evidence that drug levels of biological 
agents, such as adalimumab (ADA), are related to treatment response[41, 43–
45]. One study investigated the association between serum ADA concentrations, 
anti-ADA antibodies and therapeutic response in 121 patients with RA treated 
with adalimumab over a 28 week period [43]. Response was assessed using the 
European League Against Rheumatism (EULAR) criteria and the change in 
Disease Activity Score 28 (DAS-28) score, with serum samples collected at 
baseline, 4, 16 and 28 weeks.  Its results showed that patients with anti-ADA 
antibodies present had lower drug levels of adalimumab and showed a 
significantly poorer response to compared to those without antibodies detected 
(median(range)  was 1.2 mg/l(0.0-5.6) vs 11.0 mg/l (2.0-33.0) respectively; 
p<0.001) [43]. Results from this study also showed that good-responders had 
significantly higher plasma drug levels of adalimumab compared to non-
responders (p=0.001) [43].  
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There is also  evidence within the literature to suggest an association between 
plasma concentrations of certain cancer drugs and  therapeutic response [40]. A 
recent study assessed whether low plasma trough levels of the BCR-ABL tyrosine 
kinase inhibitor, imatinib were associated with a failure to complete a cytogenic 
response (CCR) or a major molecular response (MMR) in patients diagnosed with 
Chronic Myelogenous Leukaemia (CML) [40]. Patients were either treated with 
400mg once daily (OD) (n=50) or 600mg OD (n=18). Results from this study 
showed that trough imatinib concentrations were significantly higher in patients 
who elicited a complete cytogenic response (n=56; p=0.03) and a major 
molecular response (n=34; p<0.001) compared to those who failed to elicit either 
response [40].  
Results from the same study also revealed that plasma trough drug levels were 
highly variable amongst participants in both groups; ranging from 181 to 2947 
ng/mL. Mean trough imatinib levels and their standard deviations (SD) were 1058 
+/-557 ng/mL and 1444 +/-710 ng/mL for the 400-mg and 600-mg daily dose 
regimen respectively [40]. Multiple factors may have influenced the inter-
individual variability of in plasma drug levels, including; environmental factors, 
genetic polymorphisms, co-administered drugs and concomitant illness. The wide 
variation in plasma drug concentrations highlights the importance of 
understanding the pharmacokinetics of the drug and biological factors that may 
implicate them. This is of particular importance when plasma drug levels are 
associated with therapeutic response or adverse effects.  
There is very little evidence in the literature reporting on the relationship between 
plasma levels of glucose-lowering medications and therapeutic response. Thus, 
investigating this relationship is the logical first step in identifying mechanisms 
underpinning inter-individual variation in response to diabetes therapy. Achieved 
plasma drug levels depend on their pharmacokinetics and biological factors that 
influence them. The pharmacokinetics of the two of the most commonly 
prescribed agents prescribed after metformin, sitagliptin and gliclazide [15], are 
described below.   
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1.2.2 Overview of Sitagliptin  
1.2.2.1 Mechanism of Action 
Sitagliptin is a potent inhibitor of the dipeptidyl peptidase – 4 (DPP-4) enzyme, an 
enzyme degrades endogenous incretins. Incretins, such as glucagon like 
peptide-1 (GLP-1), are insulinotropic hormones released from the L-cells of the 
small intestine that stimulate approximately 70% of postprandial glucose-
dependent insulin secretion. In the fasted state, incretins circulate at basal levels, 
however they rapidly increase in response to meals, in order to control variations 
in glycaemia[46–48]. Glycaemic regulation is achieved via multiple mechanisms, 
including: increased insulin secretion, decreased glucagon secretion, delayed 
gastric emptying and increased satiety [46, 48, 49].  
1.2.2.2 Pharmacokinetics of sitagliptin 
Absorption  
Following the administration of a single dose of sitagliptin 100mg, 
pharmacokinetic studies performed on healthy volunteers report mean maximum 
plasma concentrations (Cmax) of 950 nmol/L (after a median of 1-4 hours) [50, 51]. 
The mean area under the time curve (AUC) plasma concentration was 8.52 
ng/mL·h [51]. Sitagliptin has a mean absolute bioavailability of 87% and its oral 
absorption is not implicated by food (therefore can be taken independently of 
meals).  In healthy volunteers, single oral doses of sitagliptin 25-400mg resulted 
in the AUC plasma concentrations increasing in a dose dependent manner [50]. 
Distribution 
Following the single 100mg intravenous administration of sitagliptin in healthy 
volunteers, the volume distribution at a steady state was reported to be 198L[51, 
52]. The fraction of sitagliptin that reversibly binds to plasma protein is low at 
38%. As it is the unbound fraction which exhibits pharmacologic effects, the 
potential for drug-drug interactions by plasma protein binding displacement is 
low. The equilibrium blood-to-plasma concentration ratio of sitagliptin is 1.21 [51, 
52]. 
Metabolism and elimination  
Metabolism serves a minor role in the elimination of sitagliptin, as approximately 
80% of the administered dose remains unchanged when excreted in the 
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urine[52].  Vicent and colleagues demonstrated how following the oral 
administration of a single radiolabelled dose of sitagliptin, the 87% of sitagliptin 
was excreted unchanged in the urine [53].  It is then excreted through glomerular 
filtration and secretion into tubules. The remainder of the drug undergoes hepatic 
metabolism  via isoenzymes CYP3A4 and CYP2C8 and excreted in the 
faeces[53–55]. The terminal elimination half-life of sitagliptin is 12.4 hours and 
the renal clearance is approximately 350 mL/min[51, 55].  
 
Results from in–vitro studies have shown that sitagliptin does not influence 
cytochrome p450 enzyme activity [51, 55]. In individuals with normal renal 
function CYP3A4 (a member of the cytochrome p450 family) minimally 
contributes to the clearance of sitagliptin, however in patients with severe renal 
impairment, this isoenzyme may have a more influential role. As a result of this, 
potent inhibitors of CYP3A4 (including commonly prescribed drugs 
clarithromycin, ketoconazole and ritonavir) may influence the pharmacokinetics 
of sitagliptin, however this is yet to be evidenced by clinical trials. Potential 
pharmacokinetic interactions of commonly prescribed drugs in the T2D cohort 
have also been assessed [51, 55], clinically significant pharmacokinetic changes 
were seen when sitagliptin was co-administered with: sulphonylureas, metformin, 
simvastatin, digoxin, warfarin and oral contraceptives.  
Influence of biological factors on pharmacokinetics 
The pharmacokinetic profile of sitagliptin is similar in the type 2 diabetes cohort 
to that observed healthy individuals [51, 55]. Data obtained from phase I and II 
pharmacokinetic studies implied that no dosage adjustments are required for 
sitagliptin on the basis of age, race, body mass index and gender[51, 55]. 
Additionally, there were no clinically significant changes in exposure to sitagliptin 
in individuals with moderate hepatic impairment (Child-Pugh score 7-9) [54]. This 
is consistent with the limited hepatic metabolism of sitagliptin, thus dosage 
adjustments in this patient population is unnecessary. Contrastingly, guidance 
recommends adjusting sitagliptin dosages for patients with chronic kidney 
disease. The normal prescribed dose of sitagliptin is 100mg OD, however in 
patients with moderate renal impairment (GFR ≥30 to <50 ml/min)., guidance 
recommends reducing the dose to 50mg OD. In patients with severe renal 
impairment (GFR <30 ml/min) or end-stage renal disease (ESRD) requiring 
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dialysis, the dose should be reduced further to 25 mg OD. Following the oral 
administration sitagliptin 50mg, plasma AUC concentrations of sitagliptin 
increased twofold and fourfold in these populations respectively when compared 
to healthy volunteers [56] (increasing the risk of unwanted side effects such as; 
nasopharyngitis, upper respiratory tract infections and headaches) [57]. 
 
1.2.2.3 Dose-response studies of sitagliptin  
A number of studies have reported the dose-response relationship for sitagliptin. 
A recent double-blinded single-dosed randomised control trial of sitagliptin 
evaluated the relationship between plasma DPP-4 activity and protection of 
intravenously infused GLP-1 [58]. Patients with T2D were administered different 
doses of sitagliptin: 0, 25, 100 and 200mg respectively. Results from this study 
revealed that sitagliptin inhibited DPP-4 activity in a dose-dependent manner 
from 25mg to 100mg  (the latter being the current recommended clinical dose in 
individuals without renal impairment) [58]. Interestingly, there was no further 
effect on DPP-4 activity with the 200mg dose when compared with 100mg [58].  
 
These findings are consistent with others reported in the literature. A previous 
double blinded, randomised control crossover trial conducted by Alba et al. [59] 
investigated whether a once daily regimen of sitagliptin 200mg was more effective 
at improving glycaemia (assessed by mean weighted glucose (MWG) over 24 
hours) when compared to sitagliptin 100mg OD. This study also assessed and 
compared differences in DPP-4 enzyme inhibition activity between the doses 
[59]. Data from this study revealed that there was no significant difference 
observed in the 24 hour MWG between 100 and 200mg sitagliptin. This finding 
suggests that a 100mg dose of sitagliptin provides maximal glucose lowering 
efficacy. DPP-4 inhibition percentages were 80% and 85% (uncorrected) and 
96% and 97% for 100mg and 200mg (corrected) of sitagliptin respectively [60].   
 
One randomised, double-blinded, placebo control trial investigated the dose-
ranging efficacy of sitagliptin in Japanese individuals with inadequate glycaemic 
control. In this study, 363 patients were randomised to one of the following arms: 
placebo, 25, 50, 100 or 200mg sitagliptin OD for 12 weeks [61]. Results showed 
no significant differences in HbA1c, FPG, post prandial glucose and glucose 
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AUC0-2h concentrations between sitagliptin doses of 50- 100- and 200mg. The 
25mg dose produced significantly smaller reductions in all of these parameters 
when compared to the 100 and 200mg doses [61].  
 
In contrast to the above studies that suggest an optimal sitagliptin dose of 100mg, 
the study performed in Japanese individuals [61]  showed no evidence of 
increased therapeutic efficacy with doses above 50mg. It is possible this 
difference may relate to differences in population characteristics, such as body 
weight or drug metabolism. Thus, understanding the influence of these clinical 
characteristics on the optimal therapeutic doses and efficacy sitagliptin is an 
avenue for further research. 
.  
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1.2.3 Overview of Gliclazide 
1.2.3.1 Mechanism of Action  
Sulphonylureas are classified as insulin secretagogues as they stimulate insulin 
secretion from pancreatic beta cells. Consequently, their adverse effects are 
manifestations of increased insulin concentrations; including hypoglycaemia and 
weight gain[58, 62]. 
Sulphonylureas exert their hypoglycaemic effect by binding to the sulphonylurea 
receptor (SUR)-1 subunit of pancreatic B-cell ATP-sensitive potassium channels. 
This closes the potassium channels, increasing the concentration of intracellular 
potassium, which causes the beta cell membrane to depolarise. As a result of 
this, voltage-dependent calcium channels open, increasing intracellular calcium 
concentrations, causing the release of insulin via exocytosis [62].   
 
1.2.3.2 Pharmacokinetic properties of Gliclazide 
Absorption  
The oral absorption of gliclazide is reported to be similar in healthy individuals 
and in patients with T2D [63]; with both populations exhibiting huge inter-
individual variability in their pharmacokinetic parameters. Following the oral 
administration of gliclazide  40-120mg pharmacokinetic studies have reported the 
average time to achieve maximum plasma concentrations (Tmax) as 2-8 hours, 
with combined literature reporting maximum plasma concentrations (Cmax) as 2.2 
μg/ml 8.0 μg/ml [63–66]. Both Cmax and Tmax  reportedly increase in a dose 
dependent manner, with steady state (trough) plasma concentrations of gliclazide 
achieved after 2 days [65]. The rate of intestinal absorption of gliclazide has been 
shown to be highly variable due to its premature dissolution in the digestive 
system. Furthermore, there is evidence to suggest that agents which increase the 
solubility of gliclazide also increase plasma gliclazide levels [67].  
 
Although absorption rates of gliclazide are highly variable, it is unclear how 
clinical features may implicate its pharmacokinetics due to limited studies. One 
small study has suggested that age influences the absorption parameters of 
gliclazide. Forette et al. compared differences in the pharmacokinetics of 
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gliclazide amongst a group of young women (n=5) mean age = 26 and a group 
of elderly women (n=5) mean age = 77 [68]. Results revealed that Cmax values 
were significantly lower and the time to achieve these values were significantly 
longer in the elderly female group compared to the younger group. [68]. 
Unfortunately, this study is limited by its small sample size, challenging its 
statistical power and increasing the likelihood that these results are due to 
chance, therefore further analysis must be conducted in a larger data set to 
validate these findings.  
 
Distribution  
Gliclazide is largely distributed in extracellular fluid, with high concentrations 
found in the liver, kidneys, skin, lungs and skeletal muscle. Gliclazide has a low 
volume distribution of 13L to 24L (or 36.3% of bodyweight) in both healthy 
individuals and those diagnosed with T2D [63, 64],  with reports of its volume 
distribution increasing with  age [68].  Gliclazide has a high protein binding affinity 
(85%-97%), increasing the potential for drug-drug interactions by plasma protein 
binding displacement.  
 
Metabolism and elimination    
Gliclazide undergoes extensive hepatic metabolism by CYP450 enzymes. 
Gliclazide metabolites include oxidised and hydroxylated derivatives in addition 
to glucuronic acid conjugates.  These metabolites are excreted in the urine via 
the kidneys (of which less than 1% of the drug remains un-metabolised). The 
reported elimination half-life of gliclazide is 8.1 hours to 20.5 hours and has a 
plasma clearance rate of gliclazide is 0.78 L/h (13 ml/min).Ings and colleagues 
reported that approximately 70% of the administered dose is excreted in the 
urine, reaching peak elimination rates 7 to 10 hours after administration[69, 70]. 
Metabolites can be detected in the urine 120 hours post administration. Faecal 
elimination, plays a minor role, accounting for approximately 11 % of the 
administered dose [64].  
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1.2.3.3 Dose- response studies of sulphonylureas 
There is data to suggest a linear relationship between sulphonylurea dosages 
and its pharmacological effects at the low end of the dose range [71, 72]. The 
recommended maximum doses for glipizide and glibenclamide/glyburide is 
40mg/day and 20mg/day respectively, however there is clinical evidence to 
indicate that maximal therapeutic effect of all of these sulphonylureas occurs at 
a dose of approximately 10mg/day, with no greater glycaemic control achieved 
at higher doses [71]. Analysis of data from UKPDS showed that in diet treated 
patients with a baseline fasting glycaemia of >10mmol/L maximum doses of 
sulphonylurea rarely achieve adequate fasting glycaemia (<6mmol/l) [10].  Some 
authors have reported that the only therapeutic benefit of increasing the dose of 
sulphonylureas was a slight prolongation of a glucose-lowering effect [72].   
 
In support of these findings,  a dose-response study of glimepride, conducted in 
308 patients with Type 2 Diabetes showed that in pariticpants who were given 
once daily doses of 1mg, 4mg and 8mg, there was no significant difference in 
glycaemic responses those who received 4mg and 8mg doses, evidenced by the 
flattening of a dose-response curve[73]. Furthermore, data obtained from two 
randomised placebo-controlled trials investigating the dose response 
characteristics of glipizide highlighted found no difference in the reduction of 
fasting, HbA1c and post prandial glycaemic response between six doses of 
glipizide (ranging from 5mg to 60mg once daily). However, further 
pharmacodynamic analysis revealed that that 5mg,10mg and 20mg doses were 
the most effective in achieving maximum reductions in HbA1c and FPG 
respectively [74].  
 
In contrast to the above findings, one placebo- controlled, double-blinded 
crossover trial suggested that the dose-response curve for sulphonylureas may 
be bell-shaped; with decreased glucose-lowering response at the higher end of 
the recommended dose range. This study  investigated the therapeutic benefits 
of increasing the dosages of glipizide over a 9 month period in patients with T2D 
(n=23) [75]. Patients were randomised into 3 groups and received glipizide doses 
of 10, 20 and 40mg of glipizide for a 3 month period in random order. Results 
revealed that following a test meal, plasma glipizide concentrations increased 
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with increasing doses, however there was no significant association with 
increasing the dose and glycaemic response (assessed by HbA1c testing and 
home glucose monitoring)  [75]. Results also showed a significantly lower insulin 
response to the test meal following the 40mg/day glipizide regimen compared to 
the 10mg/day regimen (p=0.02)  [75]. Thus, the study concluded that there may 
be no therapeutic benefit to increasing the dose of glipizide above 10mg/day with 
an increased dose potentially reducing beta cell function  [75].  
 
While a number of studies have examined dose-response relationships between 
sitagliptin and gliclazide, literature investigating the association between 
achieved drug levels of glucose-lowering agents and response is scarce; thus 
highlighting a need for further research.  
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Aims 
 
This Masters by Research aims to investigate potential mechanisms 
underpinning the variation in glucose response seen to sitagliptin and gliclazide. 
Results from this analysis will aid in determining whether a stratified approach 
can be applied to Type 2 diabetes therapy in addition to potential predictors of 
therapeutic response. This research will be performed using data collated from 
the MASTERMIND randomised control crossover pilot study (clinical trial 
identifier: (NCT01847144)).  
Objectives 
 
1. To determine whether differences in plasma drug levels explain variation 
in glucose-lowering response to DPP-4 inhibitor and sulphonylurea 
therapy.  
2. To determine whether variation in drug response is a biological attribute of 
an individual. 
a. To determine the degree to which non-concordance accounts for 
non-response to diabetes treatment in Type 2 Diabetes.  
b. To determine whether lifestyle factors, specifically measurable 
changes in weight and physical activity, is a major component of 
variation in response to therapy. 
3. To determine whether lack of response to one class of drugs is also 
associated with lack of response to an alternative agent with a different 
mechanism of action. 
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Data Source: The MASTERMIND Randomised 
Control Crossover Trial (NCT01847144) 
 
The MASTERMIND pilot study is an open label, randomized, two arm crossover 
trial conducted in the South West of England and Dundee, Scotland 
(ClinicalTrials.gov clinical trials identifier NCT01847144).  This pilot trial was 
conducted to inform and design further studies into the inter-individual variation 
in therapeutic response to glucose lowering therapy. 
2.1 Study Procedures and Flow  
2.1.1 Screening and Identification 
Potential recruits, who previously consented to be contacted about research 
projects, were identified from existing research databases. A covering letter that 
outlined the project was sent to these individuals by a Data Manager. Where 
potential recruits were identified via primary or secondary care, their clinician 
provided a brief written outline of the project and instructions and the contact 
information of the research team. 
Recruitment  
Inclusion/exclusion criteria is displayed in Table 1. Prior to recruitment, all 
potential participants were provided with written information and an opportunity 
to discuss the project with a member of the research team. All participants 
recruited to the study were required to give written informed consent and were 
excluded from the recruitment scheme if they lacked capacity.  
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Consented and assessed for eligibility n=143  
Baseline MMTT research visit n=137 
Allocated to intervention (Gliclazide) n=68 
- Received allocated intervention n=68 
- Did not receive allocated intervention n=0 
Excluded  n= 3 
- Not meeting inclusion 
criteria (n=3) 
Withdrawn n=3 
- Repeated hyperglycaemia 
n=2 
- Side effects n=1 
Allocated to intervention (Sitagliptin) n= 63 
- Received allocated intervention n=63 
- Did not receive allocated intervention n=0 
Allocated to intervention (Sitagliptin) n=65 
- Received allocated intervention n=65  
- Did not receive allocated intervention n=0 
Lost to follow-up n=0 
Discontinued intervention n=1 
- Non-compliance with study drug n=1 
Lost to follow-up n=0 
Discontinued intervention n=3 
- Repeated hyperglycaemia n=2 
- Concurrent illness n=1 
Lost to follow-up n=0  
Discontinued intervention n=0 
Allocated to intervention (Gliclazide) n=62 
- Received allocated intervention n=62 
- Did not receive allocated intervention n=0 
Follow-Up 
Lost to follow-up n=0 
Discontinued intervention n=0 
Follow-Up 
Analysis 
Randomised n=131 
Allocation 
Withdrawn n=6 
- Consent withdrawn n=2 
- Repeated hyperglycaemia n=2 
- Concurrent illness n=1 
- Other n=1 
Enrollment 
Figure 1- MASTERMIND consort diagram 
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Study Visits  
Of 143 patients that were initially eligible and gave consent, 137 participants were 
recruited and took part in the initial period of sulphonylurea withdrawal (part 1); 
All participants were invited to take part in the follow on (part 2), of which 131 
completed this stage. The second period of the study examined glycaemic 
response to 2 different treatments. A flow diagram of study visits is shown in 
Figure 2. 
2.2 Part One: Visit 1: Baseline  
Following informed written consent, a fasting blood sample (approximately 35 
mls) was obtained for the biochemical analysis, including:  saved serum and 
plasma, HbA1c, glycosylated albumin, glucose, C-peptide, liver function tests 
(ALT, Bilirubin, GGT, albumin), renal function, fasting lipid profile, pancreatic 
autoantibodies (GAD and IA2) and medication levels.   
Baseline data for the following biological/clinical parameters were also obtained, 
including: age, age at diagnosis, duration of diabetes, height, weight, waist-hip 
ratio, % body fat, ethnicity, current treatment and co-morbidities.  
Treatment Cessation and Monitoring 
Following baseline assessment, participants discontinued their sulphonylurea 
treatment.  
Visit 2: Mixed Meal Tolerance Test (location: research centre) 
At 1 week participants attended the research facility fasted, having withheld all 
other morning diabetes medication.  Prior to receiving the meal test a urine 
sample was collected and then collected again after 2 hours. Fasted blood 
samples were obtained for the following measurements: plasma glucose, 
fructosamine (a shorter term measure of glycaemia than HbA1c), C-peptide, 
insulin, and saved serum and plasma. Following this, a liquid meal of Fortisip 
250mls (mixed meal tolerance test (MMTT)) was administered and blood samples 
were taken every 30 minutes for 2 hours. Blood samples were analysed for saved 
serum and plasma, and for measurement of C-peptide, insulin and glucose. At 
the end of the test, breakfast was provided and participants took their usual 
morning diabetes medication. 
Visit 3: Assessment of Glycaemia  
At 2 weeks, a fasting blood sample was obtained for the same biochemical 
analysis (glycosylated albumin, glucose, saved plasma & serum, HbA1c) and the 
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participants’ weight was repeated.  Following the 2 week blood sample, 
participants had the option to continue to part 2 of the study, or withdraw from the 
study. Of the 137 who completed part 1, 131 participants continued to part 2. 
Reasons for discontinuation can be found in the CONSORT diagram (Figure 1). 
For participants with hyperglycaemia that required recommencing their treatment, 
they had option of participating part 2 in place of restarting usual treatment. 
2.3 Part 2: Randomisation and Adherence  
At visit 3 participants undertaking part 2 of the study were randomised to 4 weeks 
of treatment of Sitagliptin 100mg or Gliclazide 80mg once daily, taken in the 
morning. Standardized doses of the medications were given in MEMS caps 
containers. MEMS caps containers record opening times, and are the gold 
standard medication adherence. To measure physical activity participants wore 
an accelerometer for 1 week prior to the 4 week mixed meal assessment in each 
treatment arm.  
Visit 4: Mixed Meal Tolerance Test (location: research centre) 
Following 4 weeks of the first treatment, participants attended the research facility 
fasting and had their physical parameters (weight, height, waist circumference) 
measured as in previous visits, followed by a MMTT. The mixed meal test was 
performed in the same way as visit 2, except with additional samples obtained at 
3 and 4 hours.  The additional samples at 3 and 4 hours allowed for drug 
concentrations to be measured for pharmacokinetic studies. Study medication 
was administered prior to the test but any other medication was taken after the 
mixed meal test with a provided lunch. Following this, participants were asked to 
stop taking their randomised study treatment for a two week washout period (but 
were allowed to take other medication with the exception of sulphonylurea).  
Visit 5: Assessment of glycaemia and initiation of second study 
treatment  
After the two week washout period, a further fasting blood sample was obtained 
for analysis of: HbA1c, glycosylated albumin, fasting glucose and stored serum 
and plasma. Afterwards, participants were then given 4 weeks of the alternative 
treatment (participants who initially took sitagliptin will take gliclazide and vice-
versa). 
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Visit 6: Mixed Meal Tolerance Test (location: research centre) 
After the 4 week treatment period, participants attended the research facility 
fasted for a further mixed meal test and, weight and HbA1c measurement as per 
visit 4. Participants then discontinued the study medication (washout period) for 
two weeks. 
 Visit 7: Assessment of Glycaemia  
After the two week washout period, where participants took their usual medication 
without sulphonylurea/study medication, a further fasting blood test was obtained 
for the same biochemical data listed above. The study concluded at this point and 
participants’ usual sulphonylurea therapy was restarted.   
Randomisation  
The randomised order of treatments received by participants for cross-over 
section of the study (Part 2), was calculated using a randomisation table (Stats 
Direct) and was overseen by the clinical research facility statistician.  
Concomitant Therapies    
Participants were allowed to continue all non-diabetes related medication and 
were asked not to change diabetes treatment (outside the study protocol 
changes) for the duration of the study.  
Pregnancy  
A pregnancy test was offered to pre-menopausal women to ensure as pregnancy 
is an exclusion criteria for this study.  
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Figure 2 - MASTERMIND Study overview- obtained directly from 
MASTERMIND Study Protocol. 
 
  
52 
 
Subject Withdrawal  
Subjects were informed of their right to withdraw from the study at any time up 
until the samples and data were coded but not anonymised.  If participants 
withdrew after samples were anonymised, their samples and any data was 
retained and used in the analysis. For participants who permanently withdrew 
from the study, or were lost to follow-up, the reason was recorded (Figure 1: 
MASTERMIND CONSORT flow diagram). 
Ethics and Regulatory Approvals  
The study was conducted in compliance with the principles of the Declaration of 
Helsinki (1996), the principles of GCP and in accordance with all applicable 
regulatory requirements. The study was approved by the South West Research 
Ethics Committee (REC).  
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2.4 Understanding the study design 
 
Crossover Design  
The optimum method for investigating the variation in therapeutic response to 
Type 2 Diabetes remains unclear. However, crossover study designs, where 
each participant receives each treatment for a single treatment period, have the 
capacity to identify whether differences between treatments or between 
individuals contribute to the wide variation in therapeutic response to 
medications.  
Advantages of the crossover design 
One advantage of a crossover design is that participants are involved in both 
intervention arms hence serve as their own control. This not only reduces inter-
individual variability (as comparisons of different treatments are performed on the 
same individual) but also reduces the sample size needed to obtain sufficient 
power. The smaller sample size means study costs are often lower when 
compared with the more traditional parallel group study design. The stable and 
chronic nature of T2D, its measurable glycaemic endpoints and multiple 
treatment intensification options make T2D an ideal candidate for crossover trials 
for stratified research in this area.  
Washout period  
Another advantage of this crossover design is that it allows the study of glycaemic 
response associated with treatment withdrawal, this can be obtained from a 
washout period, where all study medication is withheld. If change in glycaemia 
after stopping medication is able to predict response on treatment, then this 
finding would have positive implications for clinical practice.  Data from a 
sulphonylurea withdrawal trial conducted over a 4 month period suggested, that 
glycaemic response measurement following 3-4 weeks of withdrawal as a robust 
measurement of therapeutic response[1].Treatment withdrawal data is useful as 
it can be compared to data from the initial glycaemic response to treatment and 
is a cost effective method to establish if therapeutic response is sustained and 
reproducible.  Furthermore, it reduces changes in lifestyle or adherence that are 
associated with commencing a new medication in a clinical or trial setting.  
Despite this, before changes in glycaemic response secondary to treatment 
withdrawal is assessed, non-response due to lack of adherence needs to be 
investigated.  
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Assessment of glycaemic response.  
HbA1c (glycosylated haemoglobin) is the gold standard measurement of 
glycaemic control and reflects glycaemia over a 3 month period. Despite this, 
studies investigating inter-individual variation in treatment response may not 
require a measurement of the full glycaemic response (via HbA1c).  Instead a 
measurement of that is proportional to an individual’s maximum therapeutic 
response may be sufficient, such as fructosamine. Fructosamine is a measure 
glycosylated albumin which glycaemia over a shorter time period and has high 
inter-individual validity (however is less valid compared to HbA1c) [2]. 
Furthermore, there is trial data to suggest the majority of glycaemic change 
associated with most diabetes agents, occurs within the first few weeks of 
commencing therapy [3–7].  
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Chapter 3: Precision medicine in Type 2 
Diabetes: is variation in response to sitagliptin 
and gliclazide therapy related to drug levels? 
N.B This chapter is being submitted as an original research paper to the 
journal ‘Diabetes, Obesity and Metabolism’ for publication. 
3.1 Introduction 
Trial and observational data show a wide variation in glycaemic response to 
glucose lowering therapy [1–7]. While much of this variation may be related to 
adherence and, change in lifestyle, there is increasing evidence that individual’s 
biological characteristics are associated with variation in therapeutic response[8]  
Understanding the mechanisms underpinning response variation and identifying 
robust predictors of response may allow a precision medicine (or stratified) 
approach to type 2 diabetes treatment, where therapy choice informed by an 
individual’s likely response or side effect risk, thus minimising adverse effects and 
maximising therapeutic benefit.[9] Additionally understanding reasons for 
variation in drug response could aid in dose selection and inform the development 
of new medications with lower non-response rates. 
A key candidate that may influence response to treatment is variation in achieved 
drug concentrations. In diabetes it is standard practice to use a single dose of a 
drug, regardless of patient characteristics; for example patients weighing 40kg 
and 140kg would have an identical dose for most glucose lowering medications. 
It is therefore likely that different individuals have different exposure to a drug; a 
potential cause of variation in response to therapy and side effect risk. Plasma 
drug concentrations have been shown to be associated with therapeutic 
response to treatment in several other diseases[10–12]; however whether 
variations in plasma drug levels are associated with variation in glycaemic 
response in T2D is not known. 
We aimed to investigate whether variation in plasma drug concentrations of 
sitagliptin 100mg OD and gliclazide 80mg OD (two of the most commonly 
prescribed agents after metformin in T2D)[13] are associated with biological 
characteristics of individuals, and whether variation in plasma drug 
concentrations is a major cause of variation in glucose lowering response to 
therapy. 
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3.2.1 Study Design  
We assessed the relationship between blood plasma gliclazide and sitagliptin 
levels, participant characteristics and glycaemic response in the MASTERMIND 
pilot study, an open label, randomized, two arm crossover trial conducted in the 
South West of England and Dundee, Scotland (ClinicalTrials.gov clinical trials 
identifier NCT01847144).  This pilot trial was conducted to inform and design 
further studies into the inter-individual variation in therapeutic response to 
glucose lowering therapy.  
3.2.2 Recruitment  
Potential recruits were contacted from existing clinical research databases, 
where participants had provided consent to being contacted about future 
research projects. Of 143 participants who consented to the study 68 were 
randomized to treatment sequence AB (gliclazide = A and sitagliptin =B) and 63 
were randomized to treatment sequence BA. 127 participants completed both 
arms of the trial (Figure 3 CONSORT flow diagram). 
Inclusion criteria were: a clinical diagnosis of Type 2 diabetes and were treated 
with sulphonylurea (SU) therapy (with or without metformin), age at recruitment 
>18 and <80 years, no change in diabetes treatment (new treatments or dose 
change) within last 3 months, HbA1c of ≥42 mmol/mol and ≤75 mmol/mol (≥6-
≤9%).Exclusion criteria were: renal impairment (eGFR <30 ml/min/1.73m2), 
active infection requiring antibiotics, active foot ulcer, cardiovascular disease 
occurring within the previous 3 months and pregnancy/breastfeeding.  
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Consented and assessed for eligibility n=143  
Baseline MMTT research visit n=137 
Allocated to intervention (Gliclazide) n=68 
- Received allocated intervention n=68 
- Did not receive allocated intervention n=0 
Excluded  n= 3 
- Not meeting inclusion 
criteria (n=3) 
Withdrawn n=3 
- Repeated hyperglycaemia 
n=2 
- Side effects n=1 
Allocated to intervention (Sitagliptin) n= 63 
- Received allocated intervention n=63 
- Did not receive allocated intervention n=0 
Allocated to intervention (Sitagliptin) n=65 
- Received allocated intervention n=65  
- Did not receive allocated intervention n=0 
Lost to follow-up n=0 
Discontinued intervention n=1 
- Non-compliance with study drug n=1 
Lost to follow-up n=0 
Discontinued intervention n=3 
- Repeated hyperglycaemia n=2 
- Concurrent illness n=1 
Lost to follow-up n=0  
Discontinued intervention n=0 
Allocated to intervention (Gliclazide) n=62 
- Received allocated intervention n=62 
- Did not receive allocated intervention n=0 
Follow-Up 
Lost to follow-up n=0 
Discontinued intervention n=0 
Analysed  n=93 for trough drug levels 
Excluded from analysis n= 34 
Reason for exclusion: available study budget 
Follow-Up 
Analysis 
Randomised n=131 
Allocation 
Withdrawn n=6 
- Consent withdrawn n=2 
- Repeated hyperglycaemia 
n=2 
- Concurrent illness n=1 
- Other n=1 
Enrollment 
Analysed  n=58 for total drug levels 
Excluded from analysis n= 35 
Reason for exclusion: available study budget 
Figure 3- Mastermind CONSORT flow diagram 
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3.2.2 Study procedure 
At enrolment, participants discontinued prior sulphonylurea (SU) therapy for 2 
weeks. 7 days after withdrawal of SU therapy, participants attended fasting and 
withheld morning medication for a mixed meal tolerance test (MMTT). Following 
baseline sample collection a liquid mixed meal (250ml of Fortisip Compact 
(Nutricia, Trowbridge, UK)) was consumed and blood samples were collected 
every 30 minutes for 2 hours for glucose measurement. 
At the end of the two-week washout period, participants were randomised into 
two groups, where they either received a standard dose of gliclazide (80mg) or 
sitagliptin (100mg) each in a random order.  Study medication was taken once 
daily in the morning for a period of 4 weeks; between each treatment period 
participants observed a washout period of 2 weeks (Figure 4). 
At the end of each treatment period participants attended the clinical research 
facility in the morning fasting, having withheld their morning glucose lowering 
medication. Following baseline blood sampling, participants took their study 
medication immediately followed by a mixed meal tolerance test. Blood samples 
were taken every 30 minutes for 2 hours, with additional sample collections at 3 
and 4 hours.  
All blood samples were stored at -80°C prior to analysis. Where participants were 
treated with metformin, this was withheld at all mixed meal test visits and 
administered on completion of sample collection. 
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3.2.4 Randomisation  
Randomisation for the cross-over section of the study and for the order of 
treatments received by participants was calculated using a randomisation table 
(Stats Direct, Cambridge, United Kingdom) overseen by the clinical research 
facility statistician.  
3.2.5 Biochemical analysis: Measurement of drug levels 
Analysis for plasma levels of sitagliptin and gliclazide was performed by Covance 
Laboratories (Covance Laboratories Limited, Harrogate, UK) by Protein 
Precipitation followed by Liquid Chromatography with Tandem Mass 
Spectrometric Detection (LC MS/MS). 
Other laboratory measurements 
Other laboratory analysis was undertaken by the Academic Department of Blood 
Sciences at the Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. 
Glucose was measured by enzymatic colorimetric assay GOD‑PAP using a 
Roche (Manheim, Germany) MODULAR P800 analyser. Creatinine was 
measured photometrically by Jaffé method using a Roche MODULAR P analyser. 
Fructosamine was measured using the Randox (Belfast, UK) enzymatic kit on the  
Roche Modular P800  analyser.  
 
3.2.6 Statistical analysis  
Statistical analysis was performed using STATA (StataCorp. 2015. Stata 
Statistical Software: Release 14.2 College Station, TX: StataCorp LP.). Data 
were assessed visually for distribution and where results are non-normally 
distributed, results are expressed as median(IQR). All model assumptions were 
confirmed prior to all analysis. 
 Assessing pharmacokinetic and glycaemic parameters  
Individual pharmacokinetic and pharmacodynamics parameters for sitagliptin and 
gliclazide calculated include: time to maximum concentration (Tmax), maximum 
drug concentration achieved (Cmax), peak plasma concentration and total area 
under curve at 240 minutes (AUC0-240min) levels.   
Fasting, incremental AUC0-240min (post meal glucose) and fructosamine glycaemic 
response were calculated for both sitagliptin and gliclazide and change from 
baseline was also calculated. For normally distributed results, comparison of 
change in glycaemic response between each drug was calculated using a paired 
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T-test. All AUC pharmacokinetic and glycaemic parameters were calculated 
using the trapezoid rule.  
Calculation of period/carryover effect 
The period effect (calculated by comparing the mean difference between 
sitagliptin and gliclazide treatment in the group starting on sitagliptin with that in 
the group starting on gliclazide) and the carryover effect (comparing baseline 
values for each treatment group) were calculated using Student's t test.  
Assessing relationship between plasma drug concentrations and therapeutic 
response   
We assessed the relationship between drug levels (trough and total AUC0-240min) 
and glycaemic outcomes (on therapy fasting glucose, incremental AUC0-240min 
and fructosamine) using linear regression. All linear regression models were 
adjusted for the baseline glucose measurement at initial MMTT visit (fasting, 
incremental AUC0-120 or fructosamine respectively). Analysis of incremental 
AUC0-240min was adjusted for the 2-hour incremental AUC glucose at baseline. 
Additionally, as a significant period effect was observed across glucose 
measurements (see Supplementary Table 1 and 2) all linear regression models 
were adjusted for drug order.  
While HbA1c was measured, a marked carryover effect was noted( effect(95%CI) 
-3.1 (-3.95, -2.24), p<0.0001) and therefore no further assessment of HbA1c was 
performed. 
To assess whether participants with very low drug levels has reduced glycaemic 
response, we performed a secondary categorical analysis, comparing glycaemic 
response in participants with trough drug levels <25th centile with the remaining 
participants. This analysis was performed using ANCOVA with the baseline 
measurement of the glycaemic endpoint and drug order as covariates.  
Assessing relationship between plasma concentrations and biological 
characteristics  
The association of BMI, weight, eGFR, age and gender and circulating drug levels 
(trough, total AUC0-240min and peak) were assessed using a univariable linear 
regression model; with plasma drug concentrations as fixed outcomes and the 
respective biological parameters as covariates. Whether age and eGFR were 
independently associated with drug levels was assessed using multivariable 
linear regression.   
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3.3 Results 
Participant characteristics  
Trough plasma drug levels were measured in 93 of 127 study participants who 
completed the study, per protocol with sample collection at all time points at the 
time analysis was conducted.  Post MMTT drug levels were measured at all time 
points in 58 of these participants. The number of samples measured was 
determined on the basis of order of recruitment and by the available study budget. 
Baseline characteristics are displayed in Table 2  for participants with trough drug 
levels measured (n=93) and for participants with post dose area under the curve 
drug level (n=58).  91% of those with trough drug levels were metformin treated, 
had a mean diabetes duration of 10 years, mean BMI 30.8 kg/m2 and 70% were 
male. Mean baseline glucose in these participants was 9.3 mmol/L fasting and 
mean baseline incremental AUC 417.4 mmol/L.  
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Pharmacokinetics 
Time to maximum plasma concentration (Tmax) was 180 minutes for sitagliptin 
(Figure 5a). Maximum plasma concentration (Cmax) of sitagliptin was median 
(IQR) 393.5 (112– 482) ng/mL. Tmax was not captured with gliclazide as plasma 
concentrations were still increasing after 4 hours post MMTT (Figure 5b).  
  
Figure 5- Line graph (with error bars representing the interquartile range) showing median plasma drug level of 
sitagliptin (a) and gliclazide (b) over time in on treatment mixed meal tolerance tests. Daily dose given immediately 
after time 0. 
(a) 
(b) 
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Glycaemic response to therapy 
Mean (SD) change in fasting glucose was lower with sitagliptin compared to 
gliclazide; -0.04 (1.59) vs -1.3 (1.74)mmol/L., p <0.01 respectively. In contrast , 
the average change in 2 hour incremental AUC0-240min  glucose was greater with 
sitagliptin than gliclazide: mean (SD) -47.19 (138.4) mmol/L vs -6.4(115.2) 
mmol/L, p<0.0001. Mean (SD) fructosamine change from baseline was +7.2 
(40.5) umol/L for sitagliptin and -18.8 (43.3) umol/L for gliclazide, p <0.01. 
Period and carryover effect 
There was no evidence of carryover effect influencing glucose response, 
however there was a significant period effect across most glucose 
measurements, fasting glucose effect(95%CI): -0.35 (-0.77,0.06), p=0.1, HbA1c 
effect(95%CI): -3.1 (-3.95,-2.24)  p<0.001 and fructosamine effect(95%CI): -18.5 
(-27.62,-9.38),   p<0.001 (Supplementary Table 1 and 2 – see page 79).  
Drug plasma concentrations were highly variable despite a standard dose 
regimen 
Trough plasma concentrations were highly variable with a 142.5 fold variation in 
trough levels of sitagliptin range(median) 3.7-523 (8.9) ng/mL and a 9.4 fold 
variation in trough levels of gliclazide range(median) 832-7780 (1875) ng/mL. 
High variation was also seen with total AUC0-240min plasma drug concentrations. 
There was a 39.4 fold variation in total AUC0-240min concentrations of sitagliptin 
range(median) 3367.5–132645 (66998.3) ng/mL and 9.7 fold variation for 
gliclazide 196305-1905450 (585975) ng/mL.  
Reduced renal function is associated with higher trough plasma levels of 
sitagliptin.  
The association between baseline characteristics and plasma concentrations of 
sitagliptin and gliclazide are shown in Table 3 and 4. Renal function (eGFR) and 
age were both strongly associated with plasma trough levels of sitagliptin linear 
regression β=-2.3, 95%CI (-3.64, -0.99) p=0.001 for age and β=3.9, 95%CI (0.84 
to 7), p=0.01 for renal function respectively (Figure 6b). However in multivariable 
analysis including renal function and age, only renal function was independently 
associated: eGFR β= -1.93, 95%CI (-3.4, -0.41) p=0.01, age β =1.8, 95%CI (-1.6, 
5.2), p= 0.3 respectively. These features were not associated with trough 
gliclazide level. Other clinical determinants including gender, BMI, weight and 
duration of disease were also not associated with trough plasma levels of 
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sitagliptin or gliclazide (Table 3). Similar results were seen when assessing total 
AUC0-240min drug concentrations (Table 4). 
 
 
 
 
 
 
 
 
Figure 6 - box and whisker plot demonstrating relationship between trough levels of 
gliclazide and eGFR (a) and box and whisker plot demonstrating how decreasing 
glomerular filtration rate (according to CKD classification) increases trough levels of 
sitagliptin (b).  
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Trough plasma concentrations of sitagliptin and gliclazide are not associated 
with glycaemic response. 
We found no evidence of a continuous association between trough plasma 
concentrations of sitagliptin and gliclazide and (baseline and treatment order 
adjusted) fasting glucose β=0.0005, 95%CI (-0.002, 0.003) p= 0.74 and β=-
0.0006, 95%CI (-0.0003, 0.0002) p =0.58 (Figures 7a and 7b respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7- scatter plots showing the association between: fasting glucose levels and trough 
plasma drug levels of sitagliptin (a) and .gliclazide (b) *all glucose outcomes have been adjusted 
to mean baseline glucose of 9.3mmol/L for fasting glucose outcomes and were also adjusted for 
drug order. 
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There was also no evidence of a relationship between trough drug levels and 
postprandial (incremental AUC0-240min) glucose response using the same adjusted 
linear regression analysis (Figure 8a and 8b): β= 0.18, 95%CI (0.17, 0.14) p=0.84 
for sitagliptin and β= 0.15, 95%CI (0.0004, 0.02) p=0.06 for gliclazide respectively 
Similarly, we found no evidence of a continuous association between trough 
plasma drug levels and fructosamine response; β= 0.04, 95%CI (-0.06, 0.14) 
p=0.44 for sitagliptin and β= -0.03, 95%CI (-0.01, 0.002) p=0.24 for gliclazide 
(Supplementary Table 3 and 4, see page 80) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
Figure 8-  scatter plots showing the association between: incremental AUC0-240min glucose and 
trough plasma drug levels of sitagliptin (a ) and gliclazide (b),*all glucose outcomes have been 
adjusted to mean baseline glucose of 417.4 for incremental AUC0-240min.  All glucose outcomes were 
also adjusted for drug order. 
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In categorical analysis that compared glycaemic response between those with 
the lowest trough drug levels (lowest quartile) to remainder, we found no 
association between low trough drug levels and baseline glucose and drug order 
adjusted fasting glucose levels for either agent: (sitagliptin: low mean adjusted 
glucose = 9.2 mmol/L, high mean adjusted glucose = 10.2 mmol/L. p=0.28 or 
gliclazide: low mean adjusted glucose = 8.7 mmol/L, high mean adjusted glucose 
= 7.8 mmol/L,  p=0.65) or post meal glucose response (sitagliptin p=0.16 or 
gliclazide p=0.4) (Table 5). 
  
Table 5- : analysis performed using ANCOVA to determine if individuals within the 25th centile of trough drug 
levels have a difference in glycaemic response to glucose-lowering therapy compared to those with greater 
trough drug levels, adjusted for baseline glucose and drug order. 
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Total AUC0-240min plasma concentrations of sitagliptin and gliclazide do not 
influence rise in postprandial glycaemic response to treatment 
Similarly, as shown in Figures 9a and 9b, analysis of our dataset also revealed 
no association between total AUC0-240min plasma drug concentrations and 
incremental AUC 0-240min plasma glucose: sitagliptin β =-0.06 , 95%CI (-0.00002, 
5.7x10-6) p=0.28 and gliclazide β=-0.09, 95%CI ( -7.81x10-7, 1.02x10-6), p= 0.79. 
Results were similar for total AUC0-240 glucose and fructosamine (Supplementary 
Table 3 and 4 respectively). 
  
Figure 9- scatter plots showing the association between incremental AUC0-240min plasma glucose 
and total AUC0-240min drug levels of sitagliptin (a ) and gliclazide (b)   *all glucose outcomes have 
been adjusted to mean baseline glucose of 9.3mmol/L for fasting glucose outcomes and 417.4 
for incremental AUC0-240min.  All glucose outcomes were also adjusted for drug order. 
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3.4 Discussion 
Our results did not show an association between achieved plasma drug levels 
and glucose lowering response to sitagliptin and gliclazide, despite wide 
variations in achieved drug levels. We found that trough and total AUC0-240min 
plasma drug concentrations of sitagiptin and gliclazide were highly variable 
despite all participants receiving a standard dose. Our results indicate that 
worsening renal function is associated with increased plasma levels of sitagliptin, 
which is consistent with current literature [1–3] and current prescribing guidelines. 
In contrast, plasma gliclazide levels did not alter with participant clinical 
characteristics. 
Comparison with other studies   
To our knowledge, this is the only study to examine the relationship between 
plasma drug levels and glycaemic response. Previous studies that aimed to 
determine doses of DPP-4 inhibitors have reported mean effects of DPP-4 
inhibition and glucose response with dose variation, but have not reported 
variation in plasma drug concentrations or their effects. A crossover study by 
Herman et al. observed a similar glucose lowering response and incretin effect in 
patients with T2D who were given 25 mg or 200 mg of sitagliptin after 24 hours 
when compared to that measured after 2 hours [4]. Their results also report an 
association between a DPP-4 inhibition of ≥80% (corresponding to a plasma 
concentration of 100 nM of sitagliptin) and a near to maximum reduction of 
glycaemia. These findings are further supported by a randomised controlled 
crossover trial conducted by Alba et al., who reported no significant differences 
in the percentage of DPP-4 inhibition and glucose lowering effects after 24 hours 
between sitagliptin dosages of 100 mg and 200 mg per day [5]. The lack of a 
dose-response relationship found in these studies is consistent with our findings 
that variation in stiagliptin levels do not substantially explain variation in glycaemic 
response.  These findings may be explained by a threshold effect, where 
maximum efficacy (DPP-4 enzyme inhibition) and the corresponding reduction is 
glycaemia, is achieved at very low drug doses and plasma concentrations.  
Our findings are also consistent with results from a recent meta-analysis of 31 
randomised control trials which aimed to estimate the effects of sulphonylurea 
therapy on lowering HbA1c [6].  Analysis of dose-comparison trials for two 
sulfonylurea drugs, glimepiride and glipizide, failed to demonstrate that higher 
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doses significantly lowered HbA1c more than lower doses [7]. However our 
results are in contrast to previous pharmacogenetic studies that examined the 
role of genetic variations in cytochrome p450 enzymes, enzymes pivotal to 
sulphonylurea metabolism that are associated with drug levels and therapeutic 
response. One study investigated the effects of CYP2C9 genetic polymorphisms 
on the efficacy and pharmacokinetics of the sulphonylurea glimepiride in 
Japenese subjects with T2D. It reported AUC concentrations of glimepiride to be 
2.5 folds higher and a greater reduction in HbA1c in individuals who were carriers 
of CYP2C9*1/*3 compared to carriers of the wild type [8]. This is further supported 
by analysis of retrospective data collated from the GoDarts study on 1073 incident 
sulphonylurea users (80% of which were treated with gliclazide only), which 
showed that individuals with two copies of  loss‐of‐function CYP2C9 alleles had 
a 0.5% greater reduction in HbA1c and were 3.4 folds more likely to achieve their 
glycaemic targets compared to wild carriers [9]. Of note, a further study did not 
find a relationship between these variants and gliclazide levels in a Chinese 
population [10].  
 
Strengths and Limitations  
A key strength of this study is its design as a randomised control crossover trial; 
this is the optimal design for assessing individual factors that may influence 
variation in treatment response.  The quality of the data is strengthened by its 
interventional trial setting, with a robust assessment of glycaemic response 
through mixed meal tolerance tests, and robust trough and area under the curve 
assessment of drug levels over several time points. Other strengths include the 
novelty of our research, as previously mentioned, this is the first study to identify 
that plasma drug levels are not associated with therapeutic response in second 
line diabetic agents, an area where research is limited.  
This study is limited by its modest sample size and short duration, which 
precludes assessment of HbA1c response. While our results show that drug 
levels are not a major driver of the substantial variation in short term drug 
response, our sample size is insufficient to exclude small effects or potential 
threshold effects at very low plasma drug levels. A further important limitation is 
that as baseline samples were only collected up to 2 hours, (instead of 3 and 4 
hours), meaning all analysis of incremental AUC0-240min  glucose response had to 
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be adjusted for the 2 hour incremental AUC glucose at baseline instead of the full 
4 hours. Despite this, the full 4 hour mixed meal tests these values were highly 
correlated (r= 0.82 and 0.88) for tests conducted after administration of gliclazide 
and sitagliptin respectively. Lastly, our data did not capture peak gliclazide 
concentrations, meaning our results do not provide key pharmacokinetic data for 
gliclazide such as Tmax and Cmax.  Previous studies have been successful in 
capturing peak concentrations of gliclazide over a 4 hour period post oral glucose 
tolerance test (OGTT) [11], however the constituents of the MMTT in this study 
may have decreased the gliclazide absorption rate.  
  
Clinical and research implications 
Our results support current guidance to reduce doses of sitagliptin in patients 
diagnosed with chronic kidney disease, as they show that increased plasma 
concentrations of sitagliptin are associated with worsening renal function. Our 
results also support current practice that, with the exception of sitagliptin and 
renal function, recommended doses of sitagliptin and gliclazide should not differ 
in patients with different clinical features, such as body weight.  
Our findings have potential implications in integrating a stratified approach to T2D 
treatment. We have shown that plasma drug levels of the two most commonly 
prescribed second line agents do not substantially influence therapeutic response 
to treatment. It is therefore likely that mechanisms other than plasma drug levels 
underpin the variation in therapeutic response. For clinical practice, our results 
suggest that increasing the dose of these medications in individuals with an 
apparent poor glycaemic response is unlikely to be associated with major 
glycaemic benefit. Consistent with this, there is published evidence that 
increasing sulfonylurea dose within the clinical dose range may reduce 
effectiveness, or at best result in no improvement in glycaemic response [12] .  
Our findings also have implications on precision medicine research in diabetes; 
they indicate that conducting precision medicine studies to measure plasma drug 
levels on a large scale is unlikely to significantly further to our understanding of 
the mechanisms or effective predictors of treatment response. Our results also 
suggest that characteristics and biomarkers associated with drug levels will not 
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greatly explain variation in response to these medications for the majority of 
patients.  
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3.5 Conclusion 
Understanding the mechanisms underpinning this variation and identifying robust 
predictors of response may allow the integration of precision medicine to T2D 
treatment [12]. This approach encourages therapy choice based on what most 
likely to be effective or tolerated for a group or subgroup of patients based on 
their characteristics, thus minimising adverse effects and maximising therapeutic 
benefit [13]. Lastly, understanding reasons for variation in drug response could 
aid in dose selection and assist the design of new medications with lower non-
response rates. 
In conclusion our findings show that variation in plasma drug levels do not 
substantially contribute to variation in glucose lowering response to gliclazide and 
sitagliptin therapy. It is therefore likely that variation in therapeutic response to 
these agents is driven by other factors, which should be the focus of future 
research.  
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3.6 Supplementary Tables  
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Chapter 4: can variation in adherence explain the 
variation in glycaemic response to sitagliptin and 
gliclazide therapy? 
 
4.1 Introduction   
 
A key aim of precision diabetes is to identify predictors of therapeutic response 
to glucose lowering medication. This will only benefit clinical practice if it provides 
evidence that non-response to one medicine may be associated with good 
response to another medicine with an alternative mechanism of action, rather 
than a lack of response to hypoglycaemic medication. One of the first steps in 
identifying predictors of response is understanding how much non-response to 
medication is attributed to non-adherence rather than an intrinsic lack of 
response.  
Adherence to prescribed glucose lowering therapy has frequently been identified 
as a major factor in achieving adequate glycaemic control and subsequent 
mortality rates amongst the T2D cohort[1]. Analysis of primary care records, 
adjusted for confounding factors, has shown that non-adherence to prescribed 
medications and clinic non-attendance were independent risk factors for death 
among individuals with type 2 diabetes [2].  
Few studies have examined the relationship between diabetes medication 
adherence and glucose-lowering response; with the majority of studies limited by 
their small sample size or specific focus on metformin and sulphonylurea 
therapy[3].  
If measurable variations in medication adherence is associated with the variation 
in glucose-lowering response to T2D therapy, then measuring adherence 
provides a mechanism to increase precision in future studies of treatment 
stratification in T2D. Therefore we aimed to investigate whether variation in rates 
of adherence to sitagliptin 100mg OD and gliclazide 80mg OD in a randomised 
controlled trial setting are a major cause of variation in glucose lowering response 
to these therapies. 
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4.2 Methods 
 
4.2.1 Study design  
We assessed the relationship between adherence to gliclazide and sitagliptin and 
glycaemic response in the MASTERMIND pilot study, an open label, randomized, 
two arm crossover trial conducted in the south west of England and Dundee, 
Scotland (a detailed overview of the study design can be found in Chapter 2) 
 
4.2.2 Measurement of Adherence  
MEMS Caps 
Baseline medication adherence data was obtained through self-reported 
compliance, a validated medication adherence score and practice prescription 
records. During each 4 week treatment period, participants took a single dose of 
sitagliptin (100mg) or gliclazide (80mg) once daily in the morning. All study 
medication was given in containers with Medication Event Monitoring System 
(MEMS) caps that record opening times to assist assessment of medication 
adherence (for MEMS caps are the gold standard), with remaining tablets 
counted at study visits.  
Mean Possession Ratio  
Participant adherence to study medication was calculated using a Mean 
Possession Ratio (MPR), which is the sum of the days where medication is taken 
as prescribed in a particular time period, divided by the number of days in that 
time period, expressed as a percentage. Further details of calculating MPR can 
are cited[4, 5].  
 
4.2.3 Glycaemic response. 
Fructosamine, a 2-3 week measure of glycaemia, is a key marker of therapeutic 
response for this analysis. This is because study medication was administered 
directly prior to the MMTT assessment and therefore may skew the glycaemic 
effects of poor adherence over the 4-week treatment period, particularly when 
assessing short term glycaemic response (FPG and PPG). 
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4.2.4 Statistical Analysis 
Initially, we explored at the prevalence of non-adherence defined by a MPR 
<80%. We then assessed the relationship between MPR as a continuous 
covariate and response, followed by a secondary categorical analysis to compare 
glycaemic responses to sitagliptin and gliclazide between participants who were 
adherent and non-adherent.  
 
Assessing the continuous relationship between adherence and glycaemic 
response  
We assessed the continuous relationship between medication adherence and 
glycaemic outcomes (on therapy fructosamine, fasting glucose, total AUC0-240min 
and incremental AUC0-240min (calculated using the trapezoid rule)) using linear 
regression. All linear regression models were adjusted for the baseline glucose 
measurement at initial MMTT (see Chapter 3). 
Comparison of glycaemic response in adherent participants who are adherent 
vs non-adherent.  
Participants were defined as adherent if their Medication Possession Ratio 
(MPR) ≥ 80% and non-adherent if MPR <80%.  This cut-off is based on robust 
evidence that demonstrates, reduced treatment response and increased 
mortality/hospital admissions for patients who had medication adherence rates 
<80% [3, 6].  
We assessed whether participants who were non-adherent (MPR<80%) have 
reduced glycaemic response compared to individuals who were adherent (MPR 
≥ 80%) via a  secondary categorical analysis comparing glycaemic response in 
adherent and non-adherent participants, using ANCOVA with the baseline 
measurement of the glycaemic endpoint and drug order as covariates.  
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4.3 Results 
Normally distributed data is expressed as mean(SD) and non-normal distributed 
data is given as median(IQR). 
Participants 
Of 127 participants who had completed the study per protocol, adherence data 
was collected 110 participants and 112 participants for sitagliptin and gliclazide 
respectively.  
The majority of study participants were adherent ≥80 percent 
The number of participants who were adherent n(%) to sitagliptin was 103(93.6) 
and to gliclazide was 109(97.9) (Figure 10). The median(IQR) adherence for  was 
100(96.4-100) for sitaglipin and 100 (96.4-100) for gliclazide.  
  
Figure 10 Bar chart representing number of individuals who were adherent to sitagliptin 
(left) and gliclazide (right) 
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There is no continuous association between adherence and glucose-lowering 
response to therapy.  
Linear regression analysis showed no evidence of continuous association 
between medication adherence adjusted fructosamine response: β(95%CI)= -
0.32 umol/L/% (-1.12, 0.47), p=0.42 and -0.05 umol/L/% (-0.67, 0.58) p=0.88 for 
sitagliptin and gliclazide respectively 
Our findings also show no evidence of a continuous association between 
adjusted fasting glycaemic response and adherence to sitagliptin or to gliclazide 
(Table 6): linear regression: β(95%CI) was -0.02 mmol/L/% (-0.04,0.01), p=0.17 
and 0.01 mmol/L/% (-0.02,0.03) respectively.  
When investigating the relationship between adherence to sitagliptin and total 
AUC0-240min glucose response, a significant association was noted: β(95%CI)  
0.01-0.02 mmol/L/% (-0.02, 0.03), p=0.049 after adjusting for baseline glucose 
and drug order. Contrastingly, we found no evidence of a relationship between 
adherence to gliclazide therapy and total AUC0-240min glucose concentrations.   
Similarly, we found no evidence continuous association between medication 
adherence and rise in post meal glucose levels: β(95%CI) for sitagliptin was -
2.76 mmol/L/min/% (-7.69, 2.17), p=0.27 and 0.71 mmol/L/min/%  (-3.21, 4.63) 
p=0.72 for gliclazide.  
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There was no difference in glycaemic response between adherent and non-
adherent participants to study medication.  
As shown in Table 7 categorical analysis revealed no significant difference in 
fructosamine response between individuals who were non-adherent vs adherent. 
For sitagliptin, mean fructosamine response was 377 umol/L vs 382 umol/L, p= 
0.6 and for gliclazide was 338 umol/L vs 359 umol/L, p= 0.98 for nonadherent vs 
adherent individuals respectively 
We also found no evidence in a significant difference in fasting glycaemic 
response between non-adherent vs adherent participants to either study therapy. 
Mean fasting glucose for non-adherent vs adherent participants was 9.97 mmol/L 
vs 9.7 mmol/L, p=0.9 for sitagliptin and 7.13mmol/L vs 8.52mmol/L, p=0.29 for 
gliclazide.  
We found similar results when comparing differences incremental AUC0-240min 
responses between non-adherent vs adherent individuals: the mean rise in post-
meal (incremental AUC0-240min) glucose was 430 vs 568 mmol/L/min p=0.56 for 
sitagliptin and 474 vs 589mmol/L/min, p=0.64 for gliclazide respectively.  
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4.4 Discussion  
Our results show that the majority of participants were adherent to the study 
medication in this trial setting. Consistent with the very low rates of observed non- 
adherence, variation in adherence was largely not associated with glucose-
lowering response to treatment, however a continuous association was found 
noted between total AUC0-240min glucose levels and adherence to sitagliptin. 
Lastly, we found no evidence of a difference in glycaemic response between 
individuals who were adherent and non-adherence. Our findings must be 
interpreted in the context of the small cohort, with limited power to detect 
differences in response between those with good and poor adherence.  
 
Comparison with other studies  
In support of our findings, there is strong evidence to suggest that adherence to 
sitagliptin therapy is associated with glycaemic control in patients with T2D. One 
study investigated the relationship between adherence to metformin and 
sitagliptin and glycaemic control in 677 patients with T2D in southwest Michagan. 
Results revealed a significant association between a 10% increase in non-
adherence and a 0.14%(1.5mmol/mol) increase in HbA1c [7]. In contrast to our 
findings is evidence from a larger study conducted of 1,668 patients in South 
Carolina that investigated adherence to metformin and sulphonylyrea therapy 
and glycaemic response. It reported that the mean MPR of patients who reached 
a target HbA1c of 53mmol/mol (7.0%) was 81% (compared to a mean MPR of  
72% in individuals who did not reach the target) [8], thus indicating an association 
between adherence to sulphonylurea therapy and glycaemic response.  
A recent retrospective cohort analysis obtained from large clinical practice 
electronic databases in Scotland and England: GoDARTS (Scotland) and Clinical 
Practice Research Datalink, (CPRD) (England) also contest our findings. This 
study investigated whether adherence to glucose-lowering therapy was 
associated with HbA1c levels after one year of commencing treatment.  Analysis 
of 32,634 and 2,284 found that 13% and 15% of participants from GoDarts and 
CPRD respectively were non-adherent (non-adherence was defined by an MPR 
<80% calculated using prescription record data). A smaller reduction in 1-year 
HbA1c was noted when non-adherent patients were compared with the adherent 
cohort: 0.46% (5.0 mmol/mol) for GoDarts and 0.4%(4.4 mmol/mol) for CPRD 
respectively. Interestingly, differences in glycaemic response between non-
93 
 
adherent and adherent groups varied according to the choice of hypoglycaemic 
therapy ranging from 0.38% (4.1 mmol/L to 0.75% (8.2 mmol/L)) however, 
reduced rates of adherence were consistently associated with a lower reduction 
in HbA1c [3]. A 2018 retrospective cohort analysis investigating medication 
adherence and diabetes outcomes also using data from CPRD further support 
these findings[9].  
 
Strengths and Limitations 
Strengths of this analysis include by the randomised control study design  from 
which the data was obtained and the robust measurement of adherence using 
MEMS caps (the gold standard for measuring medication adherence) [10]. 
Despite this, our findings have several key limitations. Medication hoarding is a 
recognised concern in clinical practice  [11] and although MEMS caps containers 
provide data on the number of times participants opened their medication 
containers, it cannot confirm whether participants actually took their medication.  
Furthermore, as participants were aware that they were partaking in a clinical trial 
where their medication administration was monitored, their medication-taking 
behaviour may have been altered. This challenges the clinical implications of our 
findings as they may not represent real life behaviour.  A further key limitation is 
the small sample size of the cohort; the combination of low non-adherence rates 
and modest study size mean meaning our analysis has low power to detect 
effects of non-adherence on glycaemic response. Lastly, as medication was 
administered on visit days directly prior to the MMTT, the glycaemic 
consequences of non-adherence to study medication over the 4 week treatment 
period may have been negated, particularly as only short term glycaemic 
response was assessed. Therefore, to overcome this limitation, we have placed 
more emphasis on fructosamine response, which is a marker of glycaemia over 
2-3 weeks. 
 
Implications for future research  
Our findings have implications for future research in precision diabetes; we have 
shown that adherence to two commonly used glucose-lowering agents does not 
substantially explain the variation in therapeutic response. If measurable 
differences in adherence explains the variation in glucose-lowering response to 
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diabetes therapy, then this would provide a mechanism to increase both precision 
and power in future studies in stratified diabetes.  
If adherence to medication predicts glycaemic response, as suggested by current 
literature then the next focus of precision medicine should be to identify and 
address barriers to adherence. Such barriers arise from a multitude of 
complexities including medication tolerability, often dictated by side effects such 
as hypoglycaemia, weight gain and gastrointestinal disturbances. Additional 
barriers include polypharmacy, limited patient education, complexity of 
medication regimes and cognitive impairment (common in elderly patients). [12]  
Designing medications that reduce the frequency of administration, fixed-dose 
combinations is likely to aid in overcoming these barriers and concordance 
primarily by reducing pill burden [12].  
Causes underlying patient non-adherence may alter during the course of the 
disease, however reports suggest that medication adherence is most likely to 
decrease in the first six months of commencing therapy [13]. It has been reported 
that patients with T2D who demonstrate poor adherence when commencing new 
oral hypoglycaemic agents are more likely to have a higher HbA1c and a delay 
in treatment intensification [13]. These findings have implications for treatment 
escalation and commencing de-novo therapy and suggest that if patients are 
adherent during the initial stages of commencing therapy then this may predict 
future glycaemic response.  
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4.5 Conclusion 
We have shown that in a trial setting, observed differences in medication 
adherence to sitagliptin and gliclazide do not substantially explain the variation in 
glucose-lowering response therapy. As our sample size is underpowered to 
confidently detect true effects, our analysis should be repeated in a larger dataset 
that assess at glycaemic response over a longer time period (this will help to 
validate our findings using HbA1c response). If adherence to diabetes 
medications is found to implicate therapeutic response, then collaboration 
between researchers, clinicians and patients may help in identifying ways to 
effectively overcome barriers to adherence. 
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Chapter 5 
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Chapter 5: measurable differences in weight 
and physical activity do not explain variation in 
response to sitagliptin or gliclazide therapy. 
  
5.1 Introduction  
Lifestyle interventions including weight loss and physical activity are at the 
cornerstone of T2D management [1].   Meta-analyses have demonstrated that 
structured aerobic exercise and resistance training have beneficial effects in 
reducing hyperglycaemia in T2D [2–4] however the studies included in these 
analyses are limited by their short duration and small sample size.  Evidence from 
several robust interventional trials show that real-world physical activity advice in 
the absence of dietary interventions are insufficient to effectively lower HbA1c[2, 
5, 6].  
 
The influence of lifestyle factors on glucose-lowering response to diabetes 
medication remains unclear; with evidence from randomised controlled trials and 
post-hoc analyses yielding conflicting results[7–10]. As lifestyle advice (weight 
loss and physical activity) and oral diabetes therapies are prescribed 
concomitantly and independently lower blood glucose levels, it is possible that 
variation in physical activity may explain some of the observed variation in 
response to glucose-lowering therapies. We therefore aimed to investigate 
whether measurable differences in body weight physical activity can explain the 
variation in therapeutic response to sitagliptin and gliclazide therapy by analysing 
weight and accelerometer data from the MASTERMIND randomised control 
crossover trial (Chapter 2). 
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5.2 Methods  
Assessment of weight  
At visit 1 participants had measurements of their weight(kg), height(cm) and waist 
circumference(cm) recorded to obtain baseline data, with repeated 
measurements at each study visit.  
Measurement and categorisation of physical activity  
Physical activity was measured using a Geneactiv triaxial accelerometer. 
Participants’ wore their accelerometers for 7 consecutive days (on their wrists) 
prior to on treatment visits (visit 4 and visit 6). Physical activity was classified as 
Light Physical Activity (LPA) or Moderate-to Vigorous Physical Activity (MVPA), 
depending on their mean acceleration in a 5s-epoch (ENMO). For LPA and 
MVPA this needed to be at or above 45.2 mg and 134.4mg respectively. The 
average daily minutes of physical activity (LPA or MVPA) for each treatment was 
calculated based on the 7 day recording. Calculation of LPA and MVPA was 
undertaken by Dr Lisa Philips, Lecturer in Physical activity Health Sport and 
Health Sciences, University of Exeter.  
Statistical analysis  
Weight and accelerometer data were assessed visually for their distribution, with 
non-normally distributed data expressed as median(IQR). All model assumptions 
were confirmed prior to performing all analysis. 
Assessing glycaemic parameters 
Fasting, total AUC0-240min, incremental AUC0-240min and fructosamine glycaemic 
response were calculated for both sitagliptin and gliclazide. The mean change in 
glycaemic response from baseline was also calculated.  
Assessment of weight and physical activity within participants  
We compared body weight between on-treatment visits using a paired T-test. A 
comparison between physical activity (LPA and MVPA) on sitagliptin and 
gliclazide therapy was calculated using Wilcoxon’s Matched Pairs Rank-Sign 
Test as the results were non-normally distributed.  
Assessing whether physical activity varies within an individual  
Spearman’s correlation was used to assess whether weight and physical activity 
(LPA and MVPA) varies within an individual between treatment visits, and 
between sitagliptin and gliclazide therapy.  
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Assessing whether clinical features are associated with physical 
activity  
Spearman’s correlation was used to assess whether clinical features such as 
age, BMI, weight, eGFR, diabetes duration and gender were associated with 
mean physical activity (LPA and MVPA) on treatment. The association of physical 
activity with categorical variables, including gender was assessed using Mann-
Whitney U.  
Assessing continuous relationship between lifestyle factors and 
therapeutic response to sitagliptin and gliclazide 
We assessed the continuous relationship between lifestyle factors (change in 
weight from baseline and physical activity) and on therapy glycaemic response 
response using linear regression. Linear regression models were adjusted for the 
baseline glucose measurements and drug order.  
We also used univariate linear regression to assess whether differences in 
participant mean body weight and physical activity between on-treatment visits 
(sitagliptin – gliclazide) were associated with the in differences in glycaemic 
outcomes (on therapy fasting glucose, total AUC0-240min incremental AUC0-240min) 
between study therapies, with  adjustment for drug order.  
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5.3.1 Results - Weight 
Participant weight across the study  
Mean(SD) weight on sitagliptin was 89.5(15.6)kg and was 90.1(15.8)kg on 
gliclazide (Wilcoxon’s p<0.0001). The difference in participant weight between 
sitagliptin and gliclazide therapy was -0.63(1.5)kg. The average change in weight 
from baseline was -0.9(1.9)kg and -0.28(1.8)kg on sitagliptin and gliclazide 
respectively (p<0.001), with the average total weight change across the study 
being -0.92(2.17). Changes in weight on therapy are shown in Figure 11 below.  
 
  
(a) 
(b) 
 Figure 11 histograms representing the distribution of the change in weight from baseline on sitagliptin 
therapy (a) and gliclazide therapy (b) 
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Body weight is stable within an individual  
As shown in Figure 12, body weight is stable within an individual between 
gliclazide and sitagliptin therapy r=1, p<0.001.  
 
 
 
  
Figure 12 scatter graph showing correlation between mean weight on sitagliptin (x axis) and mean 
weight on gliclazie (y axis) 
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Differences in weight on sitagliptin and gliclazide therapy were not 
associated with glucose-lowering response to treatment 
We found no evidence of a continuous association between change in weight 
from baseline on sitagliptin and gliclazide and (baseline and treatment order 
adjusted) fasting glucose response (Figure 13a and b): β =0.06 mmol/L/min, 
95%CI (-0.1,0.21) p=0.46 and β=0.11 mmol/L/min, 95%CI (-0.27,0.05) p=0.17 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(a) 
(b) 
Figure 13- scatter plots showing the association between: fasting glucose levels and change 
in weight from baseline on sitagliptin (a) and gliclazide (b) *all glucose outcomes have been 
adjusted to mean baseline glucose of 9.3mmol/L for fasting glucose outcomes and were also 
adjusted for drug order. 
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As seen in Figures 14 a and b we also found no evidence of a relationship 
between change in weight from baseline and incremental AUC0-240min glucose 
using the same linear regression analysis model β =11.1, 95%CI (-18.7,40.8) 
p=0.46 for sitagliptin and β =-2.32, 95%CI (-24.6,29.3) p=0.87  for gliclazide. 
Results were similar when assessing the association between change in 
participant weight from baseline and total AUC0-240min glucose (Table 8).  
 
 
 
 
 
 
 
 
  
  
(b) 
(a) 
Figure 14 scatter plots showing the association between: incremental AUC0-240min glucose levels 
and change in weight from baseline on sitagliptin (a) and gliclazide (b) *all glucose outcomes 
have been adjusted to mean baseline glucose of 414.7mmol/L for incremental AUC0-240min outcomes 
and were also adjusted for drug order. 
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Differences in on-treatment weight between therapies do not 
substantially explain the differences in glucose-lowering response 
between study treatments.  
Differential analysis that assessed whether differences in weight between 
sitagliptin and gliclazide therapy were associated with differences in glycaemic 
response between treatments (Table 9), revealed no evidence of a continuous 
association.  Results from linear regression analysis were β =-0.06, 95%CI (-0.3, 
0.19) p=0.67 for fasting response, β= 29.1, 95%CI (-5.39, 63.5) p=0.1 for 
incremental AUC0-240min glucose and β =- 10.04, 95%CI (-55.2, 75.3) p=0.76 for 
total AUC0-240min glucose.  
  
Table 9- relationship between differences in weight on sitagliptin and gliclazide and the differences in glycaemic 
outcomes on sitagliptin and gliclazide. All linear regression outcomes have been adjusted for drug order.  
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5.3.2 Results - Physical Activity 
Baseline participant characteristics  
Of the 127 participants that completed both arms of the study, 89 participants 
provided accelerometer data for both treatment periods. Baseline characteristics 
of participants are listed in Table 10. 
  
Physical activity was stable between treatments 
The average physical activity did not differ between participants receiving 
sitagliptin and gliclazide. Median (IQR) of LPA on sitagliptin and gliclazide was 
159(117.3-219.3)minutes/day and 164.4(131.4-209.7)minutes/day respectively 
(p for comparison=0.49). Average MVPA was 20.1(10.9-40.1)minutes/day and 
22.3(13.2-44.1)minutes/day (p=0.48) for sitagliptin and gliclazide.  
 
  
Table 10 - baseline characteristics of participants with physical activity measurements. Results expressed as median 
(IQR) unless specified otherwise. 
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Physical activity does not vary substantially within an individual 
between treatment visits or according to study therapy 
When assessing whether physical activity varied within an individual according to 
the study therapy, a significant correlation was noted between light physical 
activity on sitagliptin and gliclazide, r= 0.8 (p<0.0001) and between moderate 
activity on sitagliptin and gliclazide therapy r=0.79 (p<0.0001) (Figures 15 a and 
b respectively).  
  
Figure 15- scatter graphs showing the association between light (a) and moderate-to-
vigorous (b) physical activity during treatment period 1 and treatment period 2 
(b) 
(a) 
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Increased age and worsening renal function is associated with 
reduced physical activity. 
 
The association between baseline characteristics and physical activity are shown 
in Table 11. Our results show that age and eGFR both strongly correlated with 
physical activity (LPA and MVPA). 
 Our results show that as age increases, frequency of physical activity decreases: 
r(p-value) was -0.22(0.03) and -0.37(0.0004) for LPA and MVPA respectively. 
With regards to renal function, our results show that an increased eGFR, strongly 
correlates with an increase in physical activity, r(p-value) 0.35(0.0007) and 
0.33(0.0014). Other clinical determinants including gender, BMI, weight and 
duration of diabetes were not associated with physical activity (Table 11).  
 
  
Table 11-relationship between baseline clinical characteristics and physical activity (LPA and MVPA) using 
Spearman’s correlation, with the exception for gender (a categorical variable) which was assessed using Mann-
Whitney U.  
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Light physical activity is not associated with therapeutic response to 
sitagliptin or gliclazide therapy  
As shown in Figures 16a and 16b, we found no evidence of a continuous 
relationship between LPA and adjusted fasting glucose response to sitagliptin β= 
-0.0009 mmol/L, 95%CI (-0.005, 0.005) p= 0.97 or to gliclazide β= -0.002 mmol/L, 
95%CI (-0.008, 0.003) p= 0.38. We also found no evidence of a continuous 
association between LPA and post-meal glycaemic response to sitagliptin or 
gliclazide: β= 0.09 mmol/L/min, 95%CI (-0.31, 0.51) p=0.65 and β= 0.17 
mmol/L/min, 95%CI (-0.16, 0.51) p=0.3 respectively (Figure 16c and 16d) with 
similar results assessing total AUC0-240min and fructosamine response (Table 12). 
Moderate-to-vigorous physical activity is not associated with 
therapeutic response to sitagliptin or gliclazide  
Univariate linear regression analysis revealed no evidence of a continuous 
association between MVPA and (baseline and drug order) adjusted fasting 
glucose for sitagliptin β= -0.004 mmol/L, 95%CI(0.02, 0.01) p=0.59 or for 
gliclazide β= -0.12 mmol/L, 95%CI (-0.03, 0.03) p=0.11 (Figure 17a and b). 
Similarly, as shown in Figures 17c and d our results also show no evidence of an 
association between MVPA and incremental AUC0-240min glucose response to 
sitagliptin β= 0.71 mmol/L/min, 95%CI (-2.06, 3.47) p=0.61 or to gliclazide β= 
0.29 mmol/L/min, 95%CI (-2.02, 2.59) p=0.81. There was also no evidence of a 
relationship between MVPA and total AUC0-240min glucose and fructosamine 
response (Table 13).  
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Table 13-  continuous association between LPA and glycaemic response to sitagliptin (above) and gliclazide 
(below). Analysis performed using linear regression with outcomes adjusted for baseline glucose and drug 
order.  
Table 12- continuous association between MVPA and glycaemic response to sitagliptin (above) and gliclazide 
(below). Analysis performed using linear regression with outcomes adjusted for baseline glucose and drug 
order.  
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Differences in physical activity between sitagliptin and gliclazide 
therapy do not substantially explain the differences in glycaemic 
response between treatment regimens 
The differences in the frequency of light physical activity between treatments 
were not associated with the differences in observed glycaemia between 
sitagliptin and gliclazide, linear regression β= 0.002, 95%CI (-0.01, 0.01) p= 0.74 
and β= 0.93, 95%CI (-0.69, 2.55) p= 0.26 for fasting glucose and incremental 
AUC0-240min glucose respectively (Table 14). 
Similarly we also found no evidence of a continuous association between 
differences in MVPA between sitagliptin and gliclazide therapy and differences in 
fasting or incremental AUC0-240min glucose response: β= -0.002, 95%CI (-0.03, 
0.03) p= 0.89, and β= 2.7, 95%CI (-1.66, 7.07) p= 0.22, respectively (Table 15).  
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5.4 Discussion 
Our results have shown that measurable differences in weight and physical 
activity between sitagliptin and gliclazide therapy do not substantially explain the 
differences in short term glucose-lowering response between these treatments 
therapy. We have shown that weight and physical activity is stable within 
individual and show no continuous associated with therapeutic response to 
sitagliptin and gliclazide.   
We have identified that reduced physical activity is associated with increased age 
and reduced renal function, which is consistent with current evidence within the 
literature [1–3]. 
Comparison of our findings with weight studies 
Our weight findings are consistent with studies which show that variation in weight 
is not associated with response to GLP-1 therapy [4], but inconsistent with studies 
that show weight change (achieved by dietary interventions) is associated with 
improvement in glycaemic control [5, 6]. 
 
Few studies have investigated the direct relationship between physical activity 
and therapeutic response to diabetes medications. Most of the studies that do 
investigate the effects of intensive exercise interventions in controlled settings. 
These studies show that physical activity leads to a lower glucose after exercise 
when combined with diabetes therapy, compared to exercise alone or oral 
therapy, however their findings are limited by their small sample size.  
 
One small study conducted on 8 patients with T2D investigated whether there 
were cumulative glucose-lowering effects of a 60 minutes of an acute submaximal 
exercise intervention (performed by using a bicycle ergometer)  to 7mg 
glibenclamide compared with gibenclamide alone [7]. Its results showed that 
reductions in plasma glucose were significantly higher on days where participants 
combined exercise and glibenclamide compared exercise alone (p<0.05) [7].  
 
A larger, randomised control trial performed on 167 patients with T2D also 
investigated the metabolic effects of exercise on glycaemic response to 
sulphonylurea therapy [8]. In this study, participants were randomised in a 
double-blinded manner to either glimepiride 3mg OD or glibenclamide 10mg OD 
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for a period of 14-28 days and then further openly randomised to groups with or 
without an exercise intervention. The exercise intervention consisted of riding a 
bicycle ergometer at a pulse rate of 120 beats per minute, for a period of 1 hour.  
Paired comparisons revealed a statistically significant reduction in post-meal 
AUC plasma glucose levels in participants in the exercise and took SU therapy 
compared to participants who only took SU therapy [8].  
 
Findings from the Early Activity in Diabetes (Early ACTID) study provide a more 
robust assessment of daily physical activity on glycaemic response in the T2D 
cohort. The Early ACTID Study is a large, randomised controlled trial that 
investigated the effects of intensive physical activity advice and diet advice on 
glycaemic control in 593 individuals, newly diagnosed with T2D [5]. Participants 
were randomised to one of 3 intervention arms including: usual care (n=99), 
intensive diet intervention (n=248) and an intensive diet + physical activity 
intervention (n=246).  Approximately 40% of participants were on at least one 
glucose lowering agent. The diet intervention involved structured dietary 
consultations every 3 months which aimed to encourage 5-10% weight loss, 
whilst the physical activity intervention involved requesting participants to perform 
at least 30 minutes of brisk walking 5 days per week [5]. Physical activity and was 
calculated using an accelerometer and pedometer readings. Its results showed 
that although the dietary and dietary + physical activity interventions significantly 
improved HbA1c response compared to the control group (p=0.05 and p<0.001 
respectively), the addition of physical activity showed no additional benefit in 
improving glycaemia [5].  
 
These findings are supported by those from the Italian Diabetes and Exercise 
Study (IDES). IDES is a randomised controlled trial which investigated the effects 
of structured physical activity advice and a supervised intensive exercise 
intervention on HbA1c response in 606 patients with T2D [9] ( with approximately 
80% of participants were taking oral hypoglycaemic therapy). Participants 
randomised to the supervised exercise intervention arm (150 minutes of 
progressive mixed (aerobic and resistance) training per week) performed more 
physical activity had a significant reduction in HbA1c response (p<0.001) 
compared to participants who received physical activity counselling alone [9]. 
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Although the two latter studies [5, 9] have not directly assessed the effects of 
physical activity on the variation in therapeutic response to hypoglycaemic 
agents, they demonstrate that daily physical activity did not substantially 
influence glycaemia in the T2D cohort.  
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Strengths and limitations 
Our analysis is strengthened by the interventional study design from which the 
data was collated. Furthermore our weight and accelerometer data reflects daily 
lifestyle behaviours typical of the T2D cohort, with robust measurements of 
physical activity taken over multiple time points.  
The short duration of the MASTERMIND study limits our findings. Although our 
results demonstrate that weight and physical activity within participants remained 
stable across the study, it is unclear whether longer intervention periods would 
have captured more variation in these lifestyle factors and thus their effects on 
response to sitagliptin and gliclazide therapy. Furthermore, the 4-week 
intervention period precludes the assessment of HbA1c response (the gold 
standard measurement for monitoring glycaemic control) thus challenging the 
implications of our findings to clinical practice.  
Our findings on body weight and therapeutic response are limited by not including 
analysis on body composition; thus, the extent to which our findings reflect true 
body weight (including body fat and muscle) as opposed to variations in “noise” 
(including hydration status, daily physical activity patterns and dietary intake) is 
uncertain. Measuring participants’ body weight in a fasted state however, is likely 
to have controlled this “noise”.  
Our findings on physical activity and therapeutic response is limited by not 
including sedentary time and sleep time in our analysis. Due to the way physical 
activity was analysed, it was not possible to distinguish between these two 
variables. Evidence within the literature suggests that increased quality sleep is 
associated with improved health outcomes in diabetes[10]. Furthermore, 
emerging data indicates that interrupting sedentary time with standing or light 
physical activity may improve glycaemia and insulin sensitivity in patients T2D. 
Investigating the effects of sleep and sedentary time on response to diabetes 
medication may therefore provide avenue for future research [11].  
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5.5 Conclusion  
In conclusion, our findings demonstrate that lifestyle factors (weight and physical 
activity) are relatively stable within individuals with T2D. Evidence from our 
analysis has shown that short-term differences in weight and physical activity 
between and within an individual do not substantially explain the variation in short 
term glycaemic response to sitagliptin and gliclazide therapy. The implications of 
these findings suggest that measuring weight and physical activity in control trials 
for stratified diabetes is unlikely to be helpful.  
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Chapter 6 
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Chapter 6: is response to glucose-lowering 
therapy specific to an individual? 
 
6.1 Introduction  
There is huge variation in response to glucose-lowering therapy in T2D, with 
some individuals showing a marked response to one drug but with others eliciting 
a poor response to the same drug. The extent to which non-response reflects an 
intrinsic lack of response (attributed to reproducible biological factors which may 
be predicted) as opposed extrinsic factors (such as variations in lifestyle or 
medication concordance) is yet to be determined. For example, it is possible that 
individuals with high insulin resistance have poor response to all glucose lowering 
therapies, a finding that would challenge a precision medicine approach to T2D.  
Stratification will only be effective in T2D if it can be proven that poor response to 
one hypoglycaemic agent is associated with a good response to another agent 
with a different mechanism of action (as opposed to a lack of response to all 
hypoglycaemic agents).  
We aimed to determine whether response to glucose-lowering therapy may have 
a biological basis by investigating glycaemic responses between stopping 
sulphonylurea therapy and starting sulphonylurea and DPP-4 inhibitor therapy. 
We also assessed whether response is specific to a drug, by investigating 
whether the glucose-lowering response to one diabetes medication (gliclazide) is 
associated with the same response to another agent, with a different mechanism 
of action (sitagliptin).  
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6.2 Methods 
6.2.1 Study design 
To assess whether response to glucose-lowering medication is a biological 
characteristic of an individual, we assessed the relationship between the change 
in fasting glycaemia 1 week after stopping sulphonylurea therapy (during the 
initial washout period of the MASTERMIND study) and the change fasting 
glucose response after starting a sulphonylurea or DPP-4 inhibitor therapy in the 
same individuals as part of the study protocol.  
Although fasting glucose measurements were available at 2 weeks after SU 
withdrawal (visit 3), we assessed fasting glucose response at 1 week because 
the 2 week measurement represents the baseline for fasting glycaemic response 
for participants’ first drug. Hence, using the fasting glucose measurement after 
the 2 week washout period would consequently introduce a false correlation 
between change in fasting glucose after withdrawing SU therapy and subsequent 
on-treatment response (as the same fasting glucose measurement would have 
been used to calculate response in both outcomes).  
6.2.2 Statistical analysis  
Is the change in glycaemia after stopping sulponylurea therapy associated with 
change in glycaemia observed in starting gliclazide and sitagliptin therapy? 
Spearman’s correlation and linear regression were used to assess the 
relationship between the change in fasting glycaemia after discontinuing 
sulphonylurea therapy and the mean change in fasting glycaemic response on 
study therapy. Linear regression models were adjusted for drug order.  
Assessing whether the glucose-lowering response to sitagliptin is associated with 
the glucose lowering response to gliclazide  
The relationship between mean change in on-treatment fasting glucose response 
to sitagliptin and gliclazide therapy was assessed using spearman’s correlation 
and linear regression (with adjustment for drug order). 
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6.3 Results  
Glycaemic response after stopping sulphonylurea therapy is associated with 
glycaemic response to restarting sulphonylurea therapy 
Figure 19 shows a significant correlation between fasting glycaemia observed 1 
week after stopping sulphonylurea therapy and the reduction in fasting glycaemia 
upon restarting sulphonylurea therapy r=0.19, p=0.03, an association supported 
by linear regression analysis: β= 0.22 mmol/L, 95%CI (0.01, 0.41) p=0.04. This 
correlation indicates that an increase in fasting glycaemia from stopping SU 
therapy is associated with the reduction in fasting glycaemia upon re-starting SU 
therapy.  
 
  
Figure 18- scatter graph showing a significant correlation within an individual between change in fasting glucose 
1 week after withholding sulphonylurea therapy (x axis) and average change in fasting glucose on gliclazide 
therapy, administered per study protocol (y-axis). 
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Glycaemic response to withdrawing sulphonylurea therapy is not associated with 
glycaemic response to initiating sitagliptin therapy 
Contrastingly,  our results show no evidence of a relationship between the change 
in fasting glycaemia after stopping sulphonylurea and the change in fasting 
glycaemia to starting sitagliptin therapy: r= -0.02, p=0.79 (Figure 20), linear 
regression: β= -0.02mmol/L (-0.19, 0.15) p=0.78.  
 
 
 
 
 
 
  
Figure 19- scatter graph showing no evidence of a relationship between change in fasting glucose 1 week 
after withholding sulphonylurea therapy (x axis) and average change in fasting glucose on sitagliptin therapy 
within an individual (y-axis). 
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Fasting glycaegmic response to sitagliptin is not associated with glycaemic 
response to gliclazide 
As shown in Figure 21, we found no evidence of a significant correlation between 
the fasting glycaemic responses to sitagliptin and gliclazide therapy: r=0.008, 
p=0.99.  
 
 
 
 
 
 
 
 
Figure 20- scatter graph showing no significant correlation between fasting glycaemic responses to gliclazide 
(x- axis) and sitagliptin therapy (y-axis).  
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6.4 Discussion 
We have shown that the change in fasting glycaemia after stopping sulphonylurea 
therapy is a strong predictor of fasting glycaemic response when recommencing 
SU treatment, but is not associated with the fasting glycaemic response to 
sitagliptin therapy. The association between glycaemic responses to stopping 
and starting sulphonylurea therapies suggests that there is in part, a biological 
basis to the variation in therapeutic response to sulphonylurea therapy. These 
findings also suggest that the variation in response is not solely influenced by 
background noise (such as variations in diet, exercise and medication 
adherence).  Our results have shown that an individual’s glycaemic response may 
be specific to a drug as an individual’s fasting response to sitagliptin was not 
associated with their observed fasting glycaemic response to gliclazide.  
Comparison with other studies 
Previous studies have investigated the changes in glycaemia after stopping 
sulphonylurea therapy [1–3], however they did not investigate whether this 
change is associated with the glycaemic response to restarting sulphonylurea 
therapy or to initiating a different glucose lowering agent within an individual.  
Furthermore, we have found no other interventional studies that have 
investigated whether response to one glucose lowering agent is associated with 
the glucose-lowering response to another agent, with a differing mechanism of 
action within an individual. This largely attributed to a lack of studies investigating 
inter-individual variation to glucose lowering therapy, specifically randomised 
control crossover trials (which allow direct comparisons of therapeutic response 
to different medications within an individual). 
Strengths and limitations 
A key strength is the novelty of our findings; to our knowledge no other study has 
investigated the association in glycaemic responses between stopping and 
starting a glucose lowering agent within an individual. 
Unfortunately our findings have several limitations. Firstly, when investigating the 
relationship between glycaemic responses after stopping sulphonylurea therapy 
and starting gliclazide or sitagliptin therapy, we were limited to using fasting 
glycaemic measurements after one week of withholding sulphonylurea therapy 
(visit 2), rather than the fasting measurement after the full two week washout 
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period (visit 3). This is because the 2 week measurement represents the baseline 
for response for participants’ first study therapy, which would introduce a false 
correlation (and therefore bias) when assessing the association between change 
in glycaemia on withdrawal and subsequent response (due to use of the same 
measurement in both response outcome). Despite this, the change in fasting 
glycaemia after one week of stopping sulphonylurea therapy was similar to that 
after two weeks (mean(SD) change in fasting glucose was 1.7(1.8)mmol/L after 
one week and 1.6(2.1)mmol/L after two weeks) suggesting that the majority of 
the glycaemic effect from SU withdrawal occurred within the first week.  
Secondly, although prior to commencing the study the majority of participants 
were on an identical gliclazide regimen as per the study protocol (96%), some 
participants observed different regimens, with few participants on different 
sulphonylurea agents (including glipizide and tolbutamide). Thus, the effects of 
these different sulphonylurea therapies on fasting glucose response remains 
unclear.  
Our findings are further limited by only having fasting glucose measurements for 
the start and end of each treatment period (with post-prandial glycaemic 
assessments only conducted at the end of each treatment period). This meant 
we were unable to calculate the change in post-prandial glycaemia for each 
treatment period. Unlike gliclazide, sitagliptin has little effect on reducing fasting 
glucose and mainly exerts its glucose-lowering effects on post prandial glucose 
levels. Unfortunately as the change in post-meal glucose response to each study 
therapy could not be assessed, our analysis has been unable to determine the 
full therapeutic effect of sitagliptin. Thus, it remains unclear whether individuals 
who show a good fasting glycaemic response to gliclazide also exhibit a good 
post-prandial glycaemic response to sitagliptin.  
 
Clinical implications for future research 
As our study has only investigated short term glycaemic response to two classes 
of diabetes therapy, it is unclear whether the lack of association in glucose-
lowering response between sitagliptin and gliclazide is an isolated finding or 
whether it is representative of individual responses to all diabetes agents. In order 
to establish whether therapeutic response is specific to an individual, future 
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research would benefit from investigating glycaemic responses to multiple 
diabetes agents within an individual (achieved using a randomised control 
crossover design). As different diabetes agents work on different defective 
pathways in glucose homeostasis, all glycaemic outcomes should be measured 
at baseline and on-treatment, [4–7]), most importantly HbA1c response.  
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6.5 Conclusion 
To conclude, we have shown that the fasting glycaemic response to stopping 
sulphonylurea therapy is associated with glycaemic response to re-starting SU 
therapy (gliclazide), but not with starting sitagliptin therapy. We have also shown 
that response to gliclazide therapy is not is not associated with the therapeutic 
response to sitagliptin (hypoglycaemic agent with differing mechanisms of action. 
These findings suggest that therapeutic response to glucose-lowering therapy is 
partly attributed to a biological characteristic of an individual and is specific to 
therapy.  
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Chapter 7: Overall Conclusions from Thesis 
7.1 Summary 
In pursuit of identifying whether a stratified approach can be applied to T2D 
therapy, we investigated the potential mechanisms underpinning variation in 
therapeutic responses to sitagliptin and gliclazide. 
Our findings demonstrate that variations in plasma drug levels and lifestyle 
factors (including adherence, weight and physical activity) do not substantially 
explain the variation in therapeutic response to sitagliptin and gliclazide therapy 
in patients with T2D. Our results do however show that worsening renal function 
is associated with higher plasma drug levels of sitagliptin, supporting current 
guidance to stratify patients receiving sitagliptin according to their degree of renal 
impairment. 
We have also demonstrated that there may be a biological basis underpinning 
response to glucose-lowering medication, supported by the finding that a marked 
increase in fasting plasma glucose levels after stopping sulfonylurea therapy in 
the initial washout period correlated with a good glucose lowering response on 
restarting sulphonylurea therapy. Understanding the biological basis of this 
response and fundamentally, being able to identify individuals who exhibit this 
response could lend itself to the integration of a stratified approach to T2D 
pharmacotherapy. 
Additionally, we found no association between the glycaemic responses to 
gliclazide versus sitagliptin in a given individual. This supports stratification, which 
will only be effective if poor response to one drug is associated with a good 
response to another drug with a different mechanism of action, further research 
needs to be done to see if there is any association in treatment response using 
different glucose-lowering therapies and/or combinations. 
 
7.2 Strengths of our findings 
To our knowledge, MASTERMIND is the first randomised controlled crossover 
trial to investigate factors influencing inter-individual variation to therapeutic 
response in T2D. The findings from this novel pilot study can help to direct further 
research in the field of precision diabetes. 
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A further strength of this thesis is the study from which the data were obtained 
used a randomised controlled crossover design, minimising bias and enabling 
individuals to act as their own control. Additionally, participants were assessed at 
multiple time points, allowing a more robust assessment of their glycaemic and 
clinical parameters. 
Additionally, we assessed participants’ adherence to medication using 
Medication Event Monitoring System (MEMS) caps, which are the gold standard. 
This enabled us to reliably assess whether non-response was truly due to 
biological non-response, or due to non-compliance. 
 
7.3 Limitations of our findings 
The main limitations of the trial were the length of the study (participants received 
only four weeks of each intervention) and the sample size. 
The short study duration limited the assessment of the effect on body weight on 
glycaemia in individuals taking sitagliptin or gliclazide. It also meant we were 
unable to capture longer term variations in physical activity or change in weight 
reflective of individuals with T2D. Additionally, the short intervention periods 
impede the assessment of changes in HbA1c within our dataset, as HbA1c is 
reflective of glycaemic control over the preceding three months. 
The sample size of 137 participants meant the study was insufficiently powered 
to detect small effects (particularly when performing subgroup analyses, as 
demonstrated when analysing our adherence data). 
The above necessitates our findings to be validated in a larger data set with a 
longer study duration.  
An additional limitation of the study was that only fasting blood glucose levels 
(without post prandial blood glucose levels) were obtained for both the start and 
end of each treatment period. This meant that we were limited to only calculating 
change in fasting glycaemia (and not post prandial glycaemia) when assessing 
therapeutic response over each intervention period. 
Sitagliptin has little effect on fasting glycaemia over a short duration and mainly 
exerts its hypoglycaemic effects on post-prandial glucose, rendering us unable to 
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definitively assess its glycaemic effects. This in turn meant that we were unable 
to accurately examine the association between response to gliclazide (which 
predominantly affects fasting glucose levels) versus response to sitagliptin (which 
mainly influences post prandial glucose levels). 
Further weaknesses include a limited assessment of baseline glycaemia 
following the MMTT (visit 2), where blood was sampled up to 2 hours compared 
to 4 hours during on-treatment MMTT visits. This had the potential to limit our 
adjustment for incremental AUC0-240min glucose response. However, this is 
unlikely to have been the case in this study, as the 2-hour baseline and 4-hour 
on-treatment MMTT incremental AUC glucose values highly correlated. 
Lastly, study budget constraints limited analysis of plasma drug levels to less than 
half of participants that completed the study. 
 
7.4 Clinical implications 
The findings from the MASTERMIND pilot study have clinical implications for 
future precision medicine research in T2D. As variability in plasma drug levels 
and lifestyle factors (specifically adherence, weight and physical activity) were 
not associated with glucose-lowering response to sitagliptin and gliclazide, it is 
likely that complex measurement of these factors ( for example, by using 
accelerometry and MEMS caps) in a controlled setting, is unlikely to be beneficial. 
 
139 
 
7.5 Future research 
Avenues for future research include addressing the limitations outlined in this 
thesis. With respect to study design, we would benefit from increasing the 
duration of the intervention phases, as this would enable a more accurate 
representation of variations in body weight and physical activity in individuals with 
T2D on blood glucose lowering therapies, and the effect of these parameters on 
glycaemic response to therapy. It would also enable us to assess changes in 
HbA1c in response to glucose-lowering therapies, which is the gold standard 
means of assessing glycaemic control. 
Double blinding the interventions would minimise detection and performance bias 
and avoid overestimation of the treatment effect. Aiming to recruit more 
participants would serve to increase the precision of our findings, especially when 
performing categorical analyses; e.g. determining whether individuals who are 
non-concordant with the treatment have differences in glycaemic response 
compared to concordant individuals. Expanding the geographic location from 
which subjects are recruited would also serve to optimise the study’s external 
validity.   
Despite this, recruiting and retaining larger participant cohorts is challenged by 
several economic and participant-related barriers [1]; discussion of which lies 
beyond the scope of this thesis.  
In order to further address the question as to whether response to glucose-
lowering agents is drug-specific or an inherent attribute of individual, future 
studies would benefit from comparing responses between agents that influence 
the same glycaemic markers (for example, GLP-1 receptor agonists and DPP-4 
inhibitors mainly work by reducing post-prandial glucose). This would ensure a 
more accurate assessment of therapeutic response within individuals.  
In addition to addressing the suitability of T2D for stratification, comparative trials 
could compare overall effects of treatment; including glucose lowering effects, 
side effect profile and patient preference. This would be particularly beneficial as 
there are limited head-to-head comparisons of newer glucose lowering therapies.  
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Finally, future research in precision diabetes may benefit from randomised 
controlled crossover trials that investigate therapeutic response to multiple 
diabetes agents (including sulphonylureas, GLP-1 receptor agonists, SGLT-2 
inhibitors and thiazolidinediones), individually and in clinically appropriate 
combinations. Advantages of crossover trials include achieving adequate power 
with smaller numbers as participants serve as their own control. However, to go 
further and investigate variation in therapeutic response arising from interactions 
between participants and their treatment, future trials may benefit also from a 
repeated crossover design, where participants receives each medication more 
than once[2].  
 
7.6 Final Remarks 
Our findings demonstrate that measurable differences in drug absorption and 
lifestyle factors do not explain the substantial variation in therapeutic response to 
sitagliptin and gliclazide therapy. We have also shown that response to therapy 
is at least partly a reproducible and drug specific characteristic of an individual, 
suggesting that a stratified approach to T2D management may be feasible. 
Although future trials in stratified diabetes are necessary, our results suggest that 
detailed measurements of drug levels, adherence and physical activity are 
unlikely to be useful in this area.  
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